iCAD - 10-Q quarterly report FY2021 Q3

iCAD - 10-Q quarterly report FY2021 Q3

What is the market capitalization of a company?

DISCLAIMER

Contact

Links

falseQ3ICAD INC0000749660--12-31YesNHYesRepresents a Level 3 unobservable input, as defined in Note 8 - Fair Value Measurements, below. 0000749660 2021-09-30 0000749660 2020-12-31 0000749660 2021-07-01 2021-09-30 0000749660 2020-07-01 2020-09-30 0000749660 2021-01-01 2021-09-30 0000749660 2020-01-01 2020-09-30 0000749660 2020-02-21 0000749660 2019-12-31 0000749660 2020-09-30 0000749660 2020-02-01 2020-02-29 0000749660 2020-03-30 2020-03-30 0000749660 2021-02-21 0000749660 2021-11-01 0000749660 2021-04-27 2021-04-27 0000749660 2021-04-13 2021-04-13 0000749660 2021-03-02 2021-03-02 0000749660 2021-03-02 0000749660 2021-04-01 2021-06-30 0000749660 2021-06-30 0000749660 2020-06-30 0000749660 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2021-09-30 0000749660 us-gaap:MoneyMarketFundsMember 2021-09-30 0000749660 us-gaap:FairValueInputsLevel1Member 2021-09-30 0000749660 us-gaap:AccountingStandardsUpdate201602Member 2021-09-30 0000749660 icad:MakeWholeProvisionMember us-gaap:ConvertibleDebtMember 2021-09-30 0000749660 us-gaap:ConvertibleDebtMember 2021-09-30 0000749660 us-gaap:ShortTermContractWithCustomerMember 2021-09-30 0000749660 us-gaap:LongTermContractWithCustomerMember 2021-09-30 0000749660 icad:IcadWesternAllianceBankMember 2021-09-30 0000749660 icad:IcadWesternAllianceBankMember icad:TerminationLoansMember 2021-09-30 0000749660 icad:SiliconValleyBankMember 2021-09-30 0000749660 icad:IcadWesternAllianceBankMember icad:UnamortizedDebtIssuanceExpenseMember 2021-09-30 0000749660 icad:TwoZeroOneNineEmployeeStockPurchasePlanMember 2021-09-30 0000749660 icad:ConsolidatedReportingUnitMember 2021-09-30 0000749660 icad:DetectionMember 2021-09-30 0000749660 icad:TherapyMember 2021-09-30 0000749660 icad:TwoThousandAndTwentyFourMember 2021-09-30 0000749660 icad:TwoThousandAndTwentyFiveMember 2021-09-30 0000749660 icad:TwoThousandAndTwentySixMember 2021-09-30 0000749660 icad:TwoThousandAndTwentyThreeMember 2021-09-30 0000749660 icad:TwoThousandAndTwentyOneMember 2021-09-30 0000749660 icad:TwoThousandAndTwentyTwoMember 2021-09-30 0000749660 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0000749660 us-gaap:CostOfSalesMember 2021-07-01 2021-09-30 0000749660 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0000749660 us-gaap:SellingAndMarketingExpenseMember 2021-07-01 2021-09-30 0000749660 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0000749660 icad:BlackScholesOptionPricingModelMember 2021-07-01 2021-09-30 0000749660 us-gaap:RestrictedStockMember 2021-07-01 2021-09-30 0000749660 us-gaap:AccountingStandardsUpdate201602Member 2021-07-01 2021-09-30 0000749660 us-gaap:ProductMember 2021-07-01 2021-09-30 0000749660 us-gaap:ServiceMember 2021-07-01 2021-09-30 0000749660 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000749660 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000749660 us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0000749660 us-gaap:TransferredOverTimeMember icad:DetectionMember 2021-07-01 2021-09-30 0000749660 us-gaap:TransferredOverTimeMember icad:TherapyMember 2021-07-01 2021-09-30 0000749660 us-gaap:TransferredOverTimeMember 2021-07-01 2021-09-30 0000749660 icad:DetectionMember 2021-07-01 2021-09-30 0000749660 icad:TherapyMember 2021-07-01 2021-09-30 0000749660 us-gaap:SalesChannelDirectlyToConsumerMember icad:DetectionMember 2021-07-01 2021-09-30 0000749660 us-gaap:SalesChannelDirectlyToConsumerMember icad:TherapyMember 2021-07-01 2021-09-30 0000749660 us-gaap:SalesChannelDirectlyToConsumerMember 2021-07-01 2021-09-30 0000749660 icad:OemPartnersMember icad:DetectionMember 2021-07-01 2021-09-30 0000749660 icad:OemPartnersMember 2021-07-01 2021-09-30 0000749660 icad:ChannelPartnersMember icad:TherapyMember 2021-07-01 2021-09-30 0000749660 icad:ChannelPartnersMember 2021-07-01 2021-09-30 0000749660 us-gaap:TransferredAtPointInTimeMember icad:TherapyMember 2021-07-01 2021-09-30 0000749660 us-gaap:TransferredAtPointInTimeMember icad:DetectionMember 2021-07-01 2021-09-30 0000749660 icad:ProfessionalServicesMember 2021-07-01 2021-09-30 0000749660 icad:ProfessionalServicesMember icad:TherapyMember 2021-07-01 2021-09-30 0000749660 icad:SupplyAgreementsMember 2021-07-01 2021-09-30 0000749660 icad:SupplyAgreementsMember icad:TherapyMember 2021-07-01 2021-09-30 0000749660 icad:ServiceLineContractsMember 2021-07-01 2021-09-30 0000749660 icad:ServiceLineContractsMember icad:TherapyMember 2021-07-01 2021-09-30 0000749660 icad:ServiceLineContractsMember icad:DetectionMember 2021-07-01 2021-09-30 0000749660 icad:ProductsMember 2021-07-01 2021-09-30 0000749660 icad:ProductsMember icad:TherapyMember 2021-07-01 2021-09-30 0000749660 icad:ProductsMember icad:DetectionMember 2021-07-01 2021-09-30 0000749660 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2021-07-01 2021-09-30 0000749660 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2021-07-01 2021-09-30 0000749660 icad:TherapyMember us-gaap:ServiceMember 2021-07-01 2021-09-30 0000749660 icad:DetectionMember us-gaap:ProductMember 2021-07-01 2021-09-30 0000749660 icad:TwoZeroOneNineEmployeeStockPurchasePlanMember 2021-07-01 2021-09-30 0000749660 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000749660 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0000749660 us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0000749660 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0000749660 us-gaap:SellingAndMarketingExpenseMember 2020-07-01 2020-09-30 0000749660 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0000749660 us-gaap:RestrictedStockMember 2020-07-01 2020-09-30 0000749660 us-gaap:ProductMember 2020-07-01 2020-09-30 0000749660 us-gaap:ServiceMember 2020-07-01 2020-09-30 0000749660 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000749660 icad:ProductsMember icad:DetectionMember 2020-07-01 2020-09-30 0000749660 icad:ProductsMember icad:TherapyMember 2020-07-01 2020-09-30 0000749660 icad:ProductsMember 2020-07-01 2020-09-30 0000749660 icad:ServiceLineContractsMember icad:DetectionMember 2020-07-01 2020-09-30 0000749660 icad:ServiceLineContractsMember icad:TherapyMember 2020-07-01 2020-09-30 0000749660 icad:ServiceLineContractsMember 2020-07-01 2020-09-30 0000749660 icad:SupplyAgreementsMember icad:TherapyMember 2020-07-01 2020-09-30 0000749660 icad:SupplyAgreementsMember 2020-07-01 2020-09-30 0000749660 icad:OthersMember icad:DetectionMember 2020-07-01 2020-09-30 0000749660 icad:OthersMember 2020-07-01 2020-09-30 0000749660 icad:DetectionMember 2020-07-01 2020-09-30 0000749660 icad:TherapyMember 2020-07-01 2020-09-30 0000749660 us-gaap:TransferredAtPointInTimeMember icad:DetectionMember 2020-07-01 2020-09-30 0000749660 us-gaap:TransferredAtPointInTimeMember icad:TherapyMember 2020-07-01 2020-09-30 0000749660 us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0000749660 us-gaap:TransferredOverTimeMember icad:DetectionMember 2020-07-01 2020-09-30 0000749660 us-gaap:TransferredOverTimeMember icad:TherapyMember 2020-07-01 2020-09-30 0000749660 us-gaap:TransferredOverTimeMember 2020-07-01 2020-09-30 0000749660 icad:DetectionMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-07-01 2020-09-30 0000749660 icad:TherapyMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-07-01 2020-09-30 0000749660 us-gaap:SalesChannelDirectlyToConsumerMember 2020-07-01 2020-09-30 0000749660 icad:DetectionMember icad:OemPartnersMember 2020-07-01 2020-09-30 0000749660 icad:OemPartnersMember 2020-07-01 2020-09-30 0000749660 icad:TherapyMember icad:ChannelPartnersMember 2020-07-01 2020-09-30 0000749660 icad:ChannelPartnersMember 2020-07-01 2020-09-30 0000749660 icad:TherapyMember icad:ProfessionalServicesMember 2020-07-01 2020-09-30 0000749660 icad:ProfessionalServicesMember 2020-07-01 2020-09-30 0000749660 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000749660 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2020-07-01 2020-09-30 0000749660 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2020-07-01 2020-09-30 0000749660 icad:TherapyMember us-gaap:ServiceMember 2020-07-01 2020-09-30 0000749660 icad:DetectionMember us-gaap:ProductMember 2020-07-01 2020-09-30 0000749660 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000749660 us-gaap:RestrictedStockMember 2021-01-01 2021-09-30 0000749660 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0000749660 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0000749660 us-gaap:CostOfSalesMember 2021-01-01 2021-09-30 0000749660 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0000749660 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-09-30 0000749660 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0000749660 icad:BlackScholesOptionPricingModelMember 2021-01-01 2021-09-30 0000749660 us-gaap:RestrictedStockMember 2021-01-01 2021-09-30 0000749660 us-gaap:AccountingStandardsUpdate201602Member 2021-01-01 2021-09-30 0000749660 us-gaap:ProductMember 2021-01-01 2021-09-30 0000749660 us-gaap:ServiceMember 2021-01-01 2021-09-30 0000749660 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0000749660 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0000749660 icad:ProductsMember icad:DetectionMember 2021-01-01 2021-09-30 0000749660 icad:ProductsMember icad:TherapyMember 2021-01-01 2021-09-30 0000749660 icad:ProductsMember 2021-01-01 2021-09-30 0000749660 icad:ServiceLineContractsMember icad:DetectionMember 2021-01-01 2021-09-30 0000749660 icad:ServiceLineContractsMember icad:TherapyMember 2021-01-01 2021-09-30 0000749660 icad:ServiceLineContractsMember 2021-01-01 2021-09-30 0000749660 icad:SupplyAgreementsMember icad:TherapyMember 2021-01-01 2021-09-30 0000749660 icad:SupplyAgreementsMember 2021-01-01 2021-09-30 0000749660 icad:ProfessionalServicesMember icad:TherapyMember 2021-01-01 2021-09-30 0000749660 icad:ProfessionalServicesMember 2021-01-01 2021-09-30 0000749660 icad:DetectionMember 2021-01-01 2021-09-30 0000749660 icad:TherapyMember 2021-01-01 2021-09-30 0000749660 us-gaap:TransferredAtPointInTimeMember icad:DetectionMember 2021-01-01 2021-09-30 0000749660 us-gaap:TransferredAtPointInTimeMember icad:TherapyMember 2021-01-01 2021-09-30 0000749660 us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-09-30 0000749660 us-gaap:TransferredOverTimeMember icad:DetectionMember 2021-01-01 2021-09-30 0000749660 us-gaap:TransferredOverTimeMember icad:TherapyMember 2021-01-01 2021-09-30 0000749660 us-gaap:TransferredOverTimeMember 2021-01-01 2021-09-30 0000749660 us-gaap:SalesChannelDirectlyToConsumerMember icad:DetectionMember 2021-01-01 2021-09-30 0000749660 us-gaap:SalesChannelDirectlyToConsumerMember icad:TherapyMember 2021-01-01 2021-09-30 0000749660 us-gaap:SalesChannelDirectlyToConsumerMember 2021-01-01 2021-09-30 0000749660 icad:OemPartnersMember icad:DetectionMember 2021-01-01 2021-09-30 0000749660 icad:OemPartnersMember 2021-01-01 2021-09-30 0000749660 icad:ChannelPartnersMember icad:TherapyMember 2021-01-01 2021-09-30 0000749660 icad:ChannelPartnersMember 2021-01-01 2021-09-30 0000749660 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2021-01-01 2021-09-30 0000749660 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2021-01-01 2021-09-30 0000749660 icad:TherapyMember us-gaap:ServiceMember 2021-01-01 2021-09-30 0000749660 icad:DetectionMember us-gaap:ProductMember 2021-01-01 2021-09-30 0000749660 us-gaap:ConvertibleDebtMember icad:MonteCarloSimulationMember 2021-01-01 2021-09-30 0000749660 us-gaap:ConvertibleDebtMember 2021-01-01 2021-09-30 0000749660 icad:MakeWholeProvisionMember us-gaap:ConvertibleDebtMember 2021-01-01 2021-09-30 0000749660 icad:WesternAllianceBankMember 2021-01-01 2021-09-30 0000749660 icad:IcadWesternAllianceBankMember 2021-01-01 2021-09-30 0000749660 icad:IcadWesternAllianceBankMember icad:FinalPaymentOfLoanMember 2021-01-01 2021-09-30 0000749660 icad:TwoZeroOneNineEmployeeStockPurchasePlanMember 2021-01-01 2021-09-30 0000749660 icad:DermebxAndRadionMember icad:TherapyMember 2021-01-01 2021-09-30 0000749660 icad:DermebxAndRadionMember 2021-01-01 2021-09-30 0000749660 icad:DetectionMember icad:VucompMvuBreastDensitySoftwareMember 2021-01-01 2021-09-30 0000749660 icad:VucompMvuBreastDensitySoftwareMember 2021-01-01 2021-09-30 0000749660 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0000749660 icad:IcadWesternAllianceBankMember icad:DebtPrepaymentCostMember 2021-01-01 2021-09-30 0000749660 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0000749660 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000749660 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000749660 us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0000749660 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0000749660 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-09-30 0000749660 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0000749660 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0000749660 us-gaap:ProductMember 2020-01-01 2020-09-30 0000749660 us-gaap:ServiceMember 2020-01-01 2020-09-30 0000749660 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000749660 icad:DetectionMember icad:ProductsMember 2020-01-01 2020-09-30 0000749660 icad:TherapyMember icad:ProductsMember 2020-01-01 2020-09-30 0000749660 icad:ProductsMember 2020-01-01 2020-09-30 0000749660 icad:DetectionMember icad:ServiceLineContractsMember 2020-01-01 2020-09-30 0000749660 icad:TherapyMember icad:ServiceLineContractsMember 2020-01-01 2020-09-30 0000749660 icad:ServiceLineContractsMember 2020-01-01 2020-09-30 0000749660 icad:TherapyMember icad:SupplyAgreementsMember 2020-01-01 2020-09-30 0000749660 icad:SupplyAgreementsMember 2020-01-01 2020-09-30 0000749660 icad:DetectionMember icad:OthersMember 2020-01-01 2020-09-30 0000749660 icad:OthersMember 2020-01-01 2020-09-30 0000749660 icad:DetectionMember 2020-01-01 2020-09-30 0000749660 icad:TherapyMember 2020-01-01 2020-09-30 0000749660 icad:DetectionMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-09-30 0000749660 icad:TherapyMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-09-30 0000749660 us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-09-30 0000749660 icad:DetectionMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-09-30 0000749660 icad:TherapyMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-09-30 0000749660 us-gaap:TransferredOverTimeMember 2020-01-01 2020-09-30 0000749660 icad:DetectionMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-09-30 0000749660 icad:TherapyMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-09-30 0000749660 us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-09-30 0000749660 icad:DetectionMember icad:OemPartnersMember 2020-01-01 2020-09-30 0000749660 icad:OemPartnersMember 2020-01-01 2020-09-30 0000749660 icad:TherapyMember icad:ChannelPartnersMember 2020-01-01 2020-09-30 0000749660 icad:ChannelPartnersMember 2020-01-01 2020-09-30 0000749660 icad:ProfessionalServicesMember icad:TherapyMember 2020-01-01 2020-09-30 0000749660 icad:ProfessionalServicesMember 2020-01-01 2020-09-30 0000749660 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000749660 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2020-01-01 2020-09-30 0000749660 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2020-01-01 2020-09-30 0000749660 icad:TherapyMember us-gaap:ServiceMember 2020-01-01 2020-09-30 0000749660 icad:DetectionMember us-gaap:ProductMember 2020-01-01 2020-09-30 0000749660 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0000749660 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0000749660 us-gaap:MoneyMarketFundsMember 2020-12-31 0000749660 us-gaap:FairValueInputsLevel1Member 2020-12-31 0000749660 us-gaap:ShortTermContractWithCustomerMember 2020-12-31 0000749660 us-gaap:LongTermContractWithCustomerMember 2020-12-31 0000749660 icad:DetectionMember 2020-12-31 0000749660 icad:TermLoanAMember icad:SiliconValleyBankMember 2020-03-30 0000749660 icad:SiliconValleyBankMember us-gaap:RevolvingCreditFacilityMember 2020-03-30 0000749660 icad:SiliconValleyBankMember 2020-03-30 0000749660 icad:WesternAllianceBankMember us-gaap:BaseRateMember 2020-03-30 2020-03-30 0000749660 icad:WesternAllianceBankMember us-gaap:PrimeRateMember 2020-03-30 2020-03-30 0000749660 icad:WesternAllianceBankMember 2020-03-30 2020-03-30 0000749660 icad:SiliconValleyBankMember 2020-03-30 2020-03-30 0000749660 icad:SiliconValleyBankMember us-gaap:RevolvingCreditFacilityMember 2017-08-07 0000749660 us-gaap:MeasurementInputSharePriceMember us-gaap:ConvertibleDebtMember 2019-12-31 0000749660 us-gaap:MeasurementInputConversionPriceMember us-gaap:ConvertibleDebtMember 2019-12-31 0000749660 us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember 2019-12-31 0000749660 icad:MeasurementInputEquityVolatilityMember us-gaap:ConvertibleDebtMember 2019-12-31 0000749660 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleDebtMember 2019-12-31 0000749660 us-gaap:MeasurementInputDefaultRateMember us-gaap:ConvertibleDebtMember 2019-12-31 0000749660 us-gaap:MeasurementInputUtilizationRateMember us-gaap:ConvertibleDebtMember 2019-12-31 0000749660 icad:MeasurementInputExerciseOfDefaultRedemptionMember us-gaap:ConvertibleDebtMember 2019-12-31 0000749660 us-gaap:MeasurementInputDiscountRateMember us-gaap:ConvertibleDebtMember 2019-12-31 0000749660 us-gaap:ConvertibleDebtMember 2019-12-31 0000749660 icad:TwoZeroOneNineEmployeeStockPurchasePlanMember 2019-12-31 0000749660 us-gaap:MeasurementInputSharePriceMember us-gaap:ConvertibleDebtMember 2020-02-21 0000749660 us-gaap:MeasurementInputConversionPriceMember us-gaap:ConvertibleDebtMember 2020-02-21 0000749660 us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember 2020-02-21 0000749660 us-gaap:MeasurementInputUtilizationRateMember us-gaap:ConvertibleDebtMember 2020-02-21 0000749660 icad:TwoZeroOneNineEmployeeStockPurchasePlanMember 2019-12-01 2019-12-31 0000749660 icad:VersaVueSoftwareAndDynaCadProductAndRelatedAssetsMember icad:AssetPurchaseAgreementMember 2016-12-31 0000749660 icad:VersaVueSoftwareAndDynaCadProductAndRelatedAssetsMember icad:AssetPurchaseAgreementMember 2017-06-30 0000749660 srt:MinimumMember 2021-04-01 2021-09-30 0000749660 srt:MaximumMember 2021-04-01 2021-09-30 0000749660 us-gaap:CommonStockMember 2021-06-30 0000749660 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000749660 us-gaap:RetainedEarningsMember 2021-06-30 0000749660 us-gaap:TreasuryStockMember 2021-06-30 0000749660 us-gaap:CommonStockMember 2021-09-30 0000749660 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000749660 us-gaap:RetainedEarningsMember 2021-09-30 0000749660 us-gaap:TreasuryStockMember 2021-09-30 0000749660 us-gaap:CommonStockMember 2020-06-30 0000749660 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000749660 us-gaap:RetainedEarningsMember 2020-06-30 0000749660 us-gaap:TreasuryStockMember 2020-06-30 0000749660 us-gaap:CommonStockMember 2020-09-30 0000749660 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000749660 us-gaap:RetainedEarningsMember 2020-09-30 0000749660 us-gaap:TreasuryStockMember 2020-09-30 0000749660 us-gaap:CommonStockMember 2020-12-31 0000749660 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000749660 us-gaap:RetainedEarningsMember 2020-12-31 0000749660 us-gaap:TreasuryStockMember 2020-12-31 0000749660 us-gaap:TreasuryStockMember 2019-12-31 0000749660 us-gaap:RetainedEarningsMember 2019-12-31 0000749660 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000749660 us-gaap:CommonStockMember 2019-12-31 iso4217:USD xbrli:shares xbrli:pure utr:Year icad:Segment utr:Y iso4217:USD xbrli:shares icad:Trial icad:customer

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM

10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission file number

001-09341

iCAD, Inc.

(Exact name of registrant as specified in its charter)


Delaware		02-0377419
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

98 Spit Brook Road, Suite 100, Nashua, NH		03062
(Address of principal executive offices)		(Zip Code)

(603)

882-5200

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value	ICAD	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirement for the past 90 days. YES ☒ NO ☐.

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation

S-T

during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES ☒ NO ☐.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a

non-accelerated

filer, an emerging growth company or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule

12b-2

of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐.

Indicate by check mark whether the registrant is a shell company (as defined in Rule

12b-2

of the Exchange Act) YES ☐ NO ☒.

As of the close of business on November 1, 2021, there were 25,109,380 shares outstanding of the registrant’s Common Stock, $0.01 par value.

Table of Contents

iCAD, Inc.

INDEX


		Page
PART I	FINANCIAL INFORMATION
Item 1	Financial Statements (unaudited)
	Condensed Consolidated Balance Sheets as of September 30, 2021 (unaudited) and December 31, 2020		3
	Condensed Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2021 and September 30, 2020		4
	Condensed Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2021 and September 30, 2020		5
	Consolidated Statements of Stockholders’ Equity (unaudited) for the three and nine months ended September 30, 2021 and September 30, 2020		6
	Notes to Condensed Consolidated Financial Statements (unaudited)		8
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations		28
Item 3	Quantitative and Qualitative Disclosures about Market Risk		39
Item 4	Controls and Procedures		39
PART II	OTHER INFORMATION		40
Item 1A	Risk Factors		40
Item 6	Exhibits		41
	Signatures		42

Table of Contents

iCAD, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(In thousands except for share data)


	(Unaudited)
	September 30,			December 31,
	2021			2020
Assets
Current assets:
Cash and cash equivalents	$	35,805		$	27,186
Trade accounts receivable, net of allowance for doubtful accounts of $87 in 2021 and $111 in 2020		11,792			10,027
Inventory, net		3,290			3,144
Prepaid expenses and other current assets		1,989			1,945

Total current assets		52,876			42,302

Property and equipment, net of accumulated depreciation of $7,020 in 2021 and $6,778 in 2020		925			744
Operating lease assets		1,176			1,758
Other assets		1,657			1,527
Intangible assets, net of accumulated amortization of $8,667 in 2021 and $8,494 in 2020		741			889
Goodwill		8,362			8,362

Total assets	$	65,737		$	55,582

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	2,651		$	2,869
Accrued and other expenses		5,523			7,039
Lease payable — current portion		856			726
Deferred revenue		5,930			6,117

Total current liabilities		14,960			16,751

Lease payable, long-term portion		431			1,075
Notes payable, long-term portion		—			6,960
Deferred revenue, long-term portion		520			267
Deferred tax		5			4

Total liabilities		15,916			25,057

Commitments and Contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value: authorized 1,000,000 shares; none issued.		—			—
Common stock, $0.01 par value: authorized 60,000,000 shares; issued 25,287,837 as of September 30, 2021 and 23,693,735 as of December 31, 2020.
Outstanding 25,102,006 as of September 30, 2021 and 23,508,575 as of December 31, 2020.		253			236
Additional paid-in capital		300,017			273,639
Accumulated deficit		(249,034	)		(241,935	)
Treasury stock at cost, 185,831 shares in 2021 and 2020		(1,415	)		(1,415	)

Total stockholders’ equity		49,821			30,525

Total liabilities and stockholders’ equity	$	65,737		$	55,582

See accompanying notes to condensed consolidated financial statements.

Table of Contents

iCAD, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands except for per share data)


	Three Months Ended September 30,						Nine Months Ended September 30,
	2021			2020			2021			2020
Revenue:
Products	$	6,320		$	4,538		$	16,429		$	11,220
Service and supplies		3,041			2,591			9,401			8,027

Total revenue		9,361			7,129			25,830			19,247
Cost of revenue:
Products		1,807			1,345			4,592			2,899
Service and supplies		763			667			2,462			2,169
Amortization and depreciation		79			92			237			287

Total cost of revenue		2,649			2,104			7,291			5,355

Gross profit		6,712			5,025			18,539			13,892

Operating expenses:
Engineering and product development		2,285			1,849			6,745			5,938
Marketing and sales		3,886			2,979			10,739			9,218
General and administrative		2,658			1,834			7,461			6,476
Amortization and depreciation		64			52			178			153

Total operating expenses		8,893			6,714			25,123			21,785

Loss from operations		(2,181	)		(1,689	)		(6,584	)		(7,893	)
Interest expense		—			(115	)		(141	)		(360	)
Other income		5			10			12			85
Loss on extinguishment of debt		—			—			(386	)		(341	)
Loss on fair value of convertible debentures		—			—			—			(7,464	)

Other income (expense), net		5			(105	)		(515	)		(8,080	)
Loss before income tax expense		(2,176	)		(1,794	)		(7,099	)		(15,973	)

Tax expense		—			(3	)		—			(34	)

Net loss and comprehensive loss	$	(2,176	)	$	(1,797	)	$	(7,099	)	$	(16,007	)

Net loss per share:
Basic	$	(0.09	)	$	(0.08	)	$	(0.29	)	$	(0.73	)

Diluted	$	(0.09	)	$	(0.08	)	$	(0.29	)	$	(0.73	)

Weighted average number of shares used in computing loss per share:
Basic		25,053			23,173			24,662			21,827

Diluted		25,053			23,173			24,662			21,827

See accompanying notes to condensed consolidated financial statements.

Table of Contents

iCAD, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	For the Nine Months ended September 30,
	2021			2020
	(in thousands)
Cash flow from operating activities:
Net loss	$	(7,099	)	$	(16,007	)
Adjustments to reconcile net loss to net cash used for operating activities:
Amortization		176			234
Depreciation		242			206
Bad debt provision		(25	)		80
Stock-based compensation		2,102			2,542
Amortization of debt discount and debt costs		17			65
Loss on extinguishment of debt		386			341
Deferred tax expense		—			1
Change in fair value of convertible debentures		—			7,464
Changes in operating assets and liabilities:
Accounts receivable		(1,827	)		1,151
Inventory		(146	)		(535	)
Prepaid and other assets		493			69
Accounts payable		(217	)		96
Accrued expenses		(2,028	)		(2,322	)
Deferred revenue		65			532

Total adjustments		(762	)		9,924

Net cash used for operating activities		(7,861	)		(6,083	)

Cash flow from investing activities:
Additions to patents, technology and other		(24	)		(11	)
Additions to property and equipment		(426	)		(275	)

Net cash used for investing activities		(450	)		(286	)

Cash flow from financing activities:
Issuance of common stock pursuant to stock option plans		933			415
Issuance of common stock pursuant to Employee Stock Purchase Plan		190			209
Proceeds from issuance of common stock, net		23,229			12,174
Taxes paid related to restricted stock issuance		(59	)		(225	)
Principal payments of capital lease obligations		—			(4,638	)
Repayment of debt financing		(7,363	)		775
Repayment on line of credit		—			(2,000	)
Proceeds from notes payable		—			6,957
Debt issuance costs		—			22

Net cash provided by financing activities		16,930			13,689

Increase in cash and equivalents		8,619			7,320
Cash and cash equivalents, beginning of period		27,186			15,313

Cash and cash equivalents, end of period	$	35,805		$	22,633

Supplemental disclosure of cash flow information:
Interest paid	$	92		$	127

Taxes paid	$	—		$	34

Issuance of common stock upon conversion of debentures		—			21,164

Right-of-use assets obtained in exchange for new operating lease liabilities	$	—		$	69

See accompanying notes to condensed consolidated financial statements.

Table of Contents

Consolidated Statements of Stockholders’ Equity Year to Date

(In thousands except shares)


	Common Stock				Additional Paid-in Capital
	Number of Shares Issued		Par Value		Additional Paid-in Capital			Accumulated Deficit			Treasury Stock			Stockholders’ Equity
Balance at December 31, 2020		23,694,406		236		273,639			(241,935	)		(1,415)		$	30,525
Issuance of common stock relative to vesting of restricted stock		43,831		1		(60	)		—			—			(59	)
Issuance of common stock, net		1,393,738		14		23,215			—			—			23,229
Issuance of common stock pursuant to stock option plans		138,450		2		931			—			—			933
Issuance of common stock pursuant Employee Stock Purchase Plan		17,412		—		190			—			—			190
Stock-based compensation		—		—		2,102			—			—			2,102
Net loss		—		—		—			(7,099	)		—			(7,099	)

Balance at September 30, 2021		25,287,837	$	253	$	300,017		$	(249,034	)	$	(1,415	)	$	49,821

Consolidated Statements of Stockholders’ Equity Quarter to Date

(In thousands except shares)


	Common Stock				Additional Paid-in Capital
	Number of Shares Issued		Par Value		Additional Paid-in Capital			Accumulated Deficit			Treasury Stock			Stockholders’ Equity
Balance at June 30, 2021		25,213,302		251		299,049			(246,858	)		(1,415	)	$	51,027
Issuance of common stock relative to vesting of restricted stock		14,665		1		(60	)		—			—			(59	)
Issuance of common stock, net		54,702		1		296			—			—			297
Issuance of common stock pursuant to stock option plans		—		—		—			—			—			—
Issuance of common stock pursuant Employee Stock Purchase Plan		5,168		—		76			—			—			76
Stock-based compensation		—		—		656			—			—			656
Net loss		—		—		—			(2,176	)		—			(2,176	)

Balance at September 30, 2021		25,287,837	$	253	$	300,017		$	(249,034	)	$	(1,415	)	$	49,821

Table of Contents

Consolidated Statements of Stockholders’ Equity Year to Date

(In thousands except shares)


	Common Stock				Additional Paid-in Capital
	Number of Shares Issued		Par Value		Additional Paid-in Capital			Accumulated Deficit			Treasury Stock			Stockholders’ Equity
Balance at December 31, 2019		19,546,151	$	196	$	230,615		$	(224,325	)	$	(1,415)		$	5,071
Issuance of common stock relative to vesting of restricted stock, net		97,830		—		(225	)		—			—			(225	)
Issuance of common stock pursuant to stock option plans		94,678		1		416			—			—			417
Stock Issuance Net		1,562,500		16		12,158			—			—			12,174
Issuance of common stock pursuant Employee Stock Purchase Plan		34,857				209									209
Issuance of stock upon conversion of Debentures		1,819,466		18		21,146			—			—			21,164
Stock-based compensation		—		—		2,542									2,542
Net loss		—		—		—			(16,007	)		—			(16,007	)

Balance at September 30, 2020		23,155,482	$	231	$	266,861		$	(240,332	)	$	(1,415	)	$	25,345

Consolidated Statements of Stockholders’ Equity Quarter to Date

(In thousands except shares)


	Common Stock				Additional Paid-in Capital
	Number of Shares Issued		Par Value		Additional Paid-in Capital			Accumulated Deficit			Treasury Stock			Stockholders’ Equity
Balance at June 30, 2020		23,060,272	$	231	$	266,211		$	(238,535	)	$	(1,415	)	$	26,492
Issuance of common stock relative to vesting of restricted stock		29,106		—		(94	)		—			—			(94	)
Issuance of common stock pursuant to stock option plans		49,712		—		185			—			—			185
Stock Issuance Net		—		—		—			—			—			—
Issuance of common stock pursuant Employee Stock Purchase Plan		16,392		—		94			—			—			94
Issuance of stock upon conversion of Debentures		—		—		—			—			—			—
Stock-based compensation		—		—		465			—			—			465
Net loss		—		—		—			(1,797	)		—			(1,797	)

Balance at September 30, 2020		23,155,482	$	231	$	266,861		$	(240,332	)	$	(1,415	)	$	25,345

Table of Contents

Notes to Condensed Consolidated Financial Statements:

Note 1 – Basis of Presentation and Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated financial statements of iCAD, Inc. and its subsidiaries (together “iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of the Company’s management, these unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position of the Company at September 30, 2021, the results of operations of the Company for the three and nine-months ended September 30, 2021 and 2020, cash flows of the Company for the nine-months ended September 30, 2021 and 2020, and stockholders’ equity for the Company for the three and nine-months ended September 30, 2021 and 2020.

Although the Company believes that the disclosures made in these interim financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The accompanying interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form

10-K

for the fiscal year ended December 31, 2020 filed with the SEC on March 15, 2021. The results for the three and nine-months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2021, or any future period.

Segments

The Company

reports the results of two segments: Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of advanced image analysis and workflow products. The Therapy segment consists of radiation therapy (“Axxent”) products.

Risk and Uncertainty

On March

12, 2020, the World Health Organization declared

COVID-19

to be a pandemic. In an effort to contain and mitigate the spread of the

COVID-19

pandemic, the United States, many countries in Europe, as well as Canada and China, imposed unprecedented restrictions on travel, and there have been business closures and reductions in economic activity in countries that have had significant outbreaks of

COVID-19.

As a provider of devices and services to the health care industry, the Company’s operations have been materially affected in part due to

stay-at-home

and social distancing orders as well as uncertainty in the market. Significant uncertainty remains as to the continuing impact of the

COVID-19

pandemic on the Company’s operations and on the global economy as a whole.

Table of Contents

It is currently not possible to predict the duration of the pandemic or the time needed for economic activity to return to prior levels. The

COVID-19

pandemic has resulted in significant financial market volatility and uncertainty. Although the United States and other countries have made significant progress related to vaccinating large portions of their populations, the efficacy of each individual vaccine against the multiple strains of the

COVID-19

virus is unknown. Moreover, a new “wave” of

COVID-19

cases may exacerbate the increased levels of market disruption and volatility seen in the recent past will have an adverse effect on the Company’s ability to access capital, on its business, results of operations and financial condition, and on the market price of its common stock.

The Company’s results for the quarter ending September 30, 2021 reflect a negative impact from the

COVID-19

pandemic due to some healthcare facilities’ additional focus on

COVID-19

and from the effect on our customers and po

ential customers of supply chain issues relating thereto. Although the Company does not provide guidance to investors relating to its future results of operations, its results for the quarter ending December 31, 2021, and possibly future quarters, could reflect a continued negative impact from the

COVID-19

pandemic for similar reasons. The duration and severity of the pandemic is unknown, and so the continued effect on the Company’s results over the long term is uncertain.

Although the Company did not experience any material impact to trade accounts receivable losses in the quarter ended September 30, 2021, the Company’s exposure may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current

COVID-19

pandemic, or other customer-specific factors. The Company has not historically experienced significant trade account receivable losses, but it is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade account receivables as clinical customers’ cash flows are impacted by healthcare business considerations related to the

COVID-19

pandemic.

Recently Adopted Accounting Pronouncements

There are no significant recently adopted accounting pronouncements. For a full list of the Company’s response to all relevant recent accounting pronouncements, please refer to Note 13 below.

Revenue Recognition

Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration which the Company expects to be entitled to receive in exchange for these goods or services and excludes any sales incentives or taxes collected from customers which are subsequently remitted to government authorities.

Table of Contents

Disaggregation of Revenue

The following tables presents

the

Company’s revenues disaggregated

major good or service line, timing of revenue recognition, and sales channel, reconciled to its reportable segments (in thousands).


	Three months ended September 30, 2021
	Reportable Segments
	Detection		Therapy		Total
Major Goods/Service Lines
Products	$	4,454	$	2,358	$	6,812
Service contracts		1,554		398		1,952
Supply and source usage agreements		—		562		562
Professional services		—		35		35
Other		—		—		—

	$	6,008	$	3,353	$	9,361
Timing of Revenue Recognition
Goods transferred at a point in time	$	4,454	$	2,393	$	6,847
Services transferred over time		1,554		960		2,514

	$	6,008	$	3,353	$	9,361
Sales Channels
Direct sales force	$	3,629	$	1,403	$	5,032
OEM partners		2,379		—		2,379
Channel partners		—		1,950		1,950

	$	6,008	$	3,353	$	9,361

	Nine months ended September 30, 2021
	Reportable Segments
	Detection		Therapy		Total
Major Goods/Service Lines

Products	$	11,778	$	6,580	$	18,358
Service contracts		4,737		1,109		5,846
Supply and source usage agreements		—		1,572		1,572
Professional services		—		54		54
Other		—		—		—

	$	16,515	$	9,315	$	25,830

Timing of Revenue Recognition
Goods transferred at a point in time	$	11,778	$	6,633	$	18,411
Services transferred over time		4,737	$	2,682		7,419

	$	16,515	$	9,315	$	25,830
Sales Channels
Direct sales force	$	10,691	$	3,632	$	14,323
OEM partners		5,824		—		5,824
Channel partners		—		5,683		5,683

	$	16,515	$	9,315	$	25,830

Table of Contents


	Three months ended September 30, 2020
	Reportable Segments
	Detection		Therapy		Total
Major Goods/Service Lines
Products	$	3,889	$	1,038	$	4,927
Service contracts		1,400		347		1,747
Supply and source usage agreements		—		444		444
Professional services		—		9		9
Other		2		—		2

	$	5,291	$	1,838	$	7,129

Timing of Revenue Recognition
Goods transferred at a point in time	$	3,889	$	1,051	$	4,940
Services transferred over time		1,402		787		2,189

	$	5,291	$	1,838	$	7,129

Sales Channels
Direct sales force	$	2,904	$	857	$	3,761
OEM partners		2,387		—		2,387
Channel partners		—		981		981

	$	5,291	$	1,838	$	7,129


	Nine months ended September 30, 2020
	Reportable Segments
	Detection		Therapy		Total
Major Goods/Service Lines

Products	$	9,690	$	2,959	$	12,649
Service contracts		4,151		1,079		5,230
Supply and source usage agreements		—		1,305		1,305
Professional services		—		20		20
Other		43		—		43

	$	13,884	$	5,363	$	19,247

Timing of Revenue Recognition
Goods transferred at a point in time	$	9,731	$	3,039	$	12,770
Services transferred over time		4,153		2,324		6,477

	$	13,884	$	5,363	$	19,247

Sales Channels
Direct sales force	$	7,785	$	3,131	$	10,916
OEM partners		6,099		—		6,099
Channel partners		—		2,232		2,232

	$	13,884	$	5,363	$	19,247

Table of Contents

Products.

Product revenue consists of sales of cancer detection products, cancer therapy systems, cancer therapy applicators (including disposable applicators) and other accessories that are typically shipped with a cancer therapy system. The Company transfers control and generally recognizes a sale when the product is shipped from the manufacturing or warehousing facility to the customer unless an individual contract states otherwise.

Service Contracts.

The Company sells service contracts under which it provides professional services, including product installations, maintenance, training, and service repairs, and in certain cases equipment leases, to hospitals, imaging centers, radiology practices, radiation oncologists and treatment centers. These contracts represent separate performance obligations of the Company. The Company allocates revenue to each performance obligation based on the Standalone Selling Price (“SSP”). Revenue for lease and

non-lease

components, or the entire arrangement when accounted for under ASC 606, “Revenue from Contracts with Customers” (“ASC 606”), is recognized on a straight-line basis over the term of the agreement. The service contracts range from 12 months to 48 months. The Company typically receives payment at the inception of the contract and recognizes revenue on a straight-line basis over the term of the agreement.

Supply and Source Usage Agreements.

Revenue from supply and source usage agreements is recognized on a straight-line basis over the term of the supply or source usage agreement.

These agreements represent a separate performance obligation of the Company. The Company allocates revenue to each performance obligation based on the SSP.

Professional Services.

Revenue from fixed fee service contracts is recognized on a straight-line basis over the term of the agreement. Revenue from professional service contracts entered into with customers on a time and materials basis is recognized over the term of the agreement in proportion to the costs incurred in satisfying the obligations under the contract.

Other.

Other revenue consists primarily of miscellaneous products and services. The Company transfers control and recognizes a sale when the product is shipped from the manufacturing or warehousing facility to the customer or the installation services are performed.

Contract Balances

Contract liabilities are a component of deferred revenue, current contract assets are a component

of prepaid and other assets and

non-current

contract assets are a component of other assets.

The following table provides information about receivables, current and

non-current

contract assets, and contract liabilities from contracts with customers (in thousands).

Contract balances


Contract balances
	Balance at		Balance at
	September 30, 2021		December 31, 2020
Receivables, which are included in ‘Trade accounts receivable’	$	11,792	$	10,027
Current contract assets, which are included in “Prepaid and other assets”		658		481
Non-current contract assets, which are included in “other assets”		1,602		1,434
Contract liabilities, which are included in “Deferred revenue”		6,450		6,384

Timing of revenue recognition may differ from timing of invoicing of customers. The Company records a receivable when revenue is recognized prior to receipt of cash payment and the Company has the unconditional right to such consideration, or unearned revenue when cash payments are received or due in advance of performance. For multi-year agreements, the Company generally invoices customers annually at the beginning of each annual service period.

The Company records net contract assets or contract liabilities on a

contract-by-contract

basis. The Company records a contract asset for unbilled revenue when the Company’s performance is in excess of amounts invoiced or invoiceable. The Company classifies the net contract asset as either a current or

non-current

based on the expected timing of the Company’s right to invoice under the terms of the contract. The current contract asset balance primarily relates to the net unbilled revenue balances with two significant customers, which the Company expects to be able to invoice within one year. The

non-current

contract asset balance consists of net unbilled revenue balances with one customer which the Company expects to be able to invoice in more than one year.

Table of Contents

Contract liabilities, or deferred revenue from contracts with customers, is primarily composed of fees related to long-term service arrangements, which are generally invoiced in advance. Deferred revenue also includes payments for installation and training that has not yet been completed and other offerings for which the Company has been paid in advance and earn

the revenue when it transfers control of the product or service. The balance of deferred revenue at September 30, 2021 and December 31, 2020 was as follows (in thousands):


Contract liabilities	September 30, 2021		December 31, 2020

Short term	$	5,930	$	6,117
Long term		520		267

Total	$	6,450	$	6,384

Changes in deferred revenue from contracts with customers were as follows (in thousands):


	Nine Months Ended September 30, 2021

Balance at beginning of period	$	6,384
Deferral of revenue		9,761
Recognition of deferred revenue		(9,695	)

Balance at end of period	$	6,450

The Company

expects to recognize estimated revenues related to performance obligation that

are

unsatisfied (or partially satisfied) in

the

amounts of approximately $2.3 million in 2021, $4.3 million in 2022, and $1.7

million in 2023, $1.1 million in 2024, $1.1 million in 2025 and $0.2 million in 2026.

Note 2 – Net Loss per Common Share

The Company’s basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period.

A summary of the Company’s calculation of net loss per share is as follows (in thousands except per share amounts):


	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2021			2020			2021			2020
Net loss	$	(2,176	)	$	(1,797	)	$	(7,099	)	$	(16,007	)

Shares used in the calculation of basic and diluted net loss per share		25,053			23,173			24,662			21,827

Diluted shares used in the calculation of net loss per share		25,053			23,173			24,662			21,827

Net loss per share—basic and diluted	$	(0.09	)	$	(0.08	)	$	(0.29	)	$	(0.73	)

Table of Contents

The shares of the Company’s common stock issuable upon the exercise of convertible securities, stock options and vesting of restricted stock that were excluded from

the

calculation of diluted net loss per share because their effect would have been antidilutive are as follows:


	As of September 30,

	2021		2020

Stock options		2,509,511		1,971,704
Restricted stock		1,750		29,166

Total		2,511,261		2,000,870

Note 3 – Inventory

Inventory is valued at the lower of cost or net realizable value, with cost determined by the

first-in,

first-out

method. The Company regularly reviews inventory quantities on hand and records a reserve for excess and/or obsolete inventory primarily based upon the estimated usage of its inventory as well as other factors. Inventory consisted of the following (in thousands) and includes an inventory reserve of approximately

$0.2 million for both periods ended September 30, 2021

and

December 31, 2020.


	September 30, 2021			December 31, 2020
Raw materials	$	1,845		$	1,538
Work in process		104			76
Finished Goods		1,567			1,774

Inventory Gross		3,516			3,388
Inventory Reserve		(225	)		(244	)

Inventory Net	$	3,290		$	3,144

Table of Contents

Note 4 – Financing Arrangements

(a) Loan and Security Agreement – Western Alliance Bank

On March 30, 2020, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Western Alliance Bank (the “Bank”) that provided an initial term loan (“Term Loan”) facility of $7.0 million and a $5.0 million revolving line of credit.

nterest in arrears on the Term Loan began to be repaid on April 1, 2020 and will continue to be paid on the first of each successive month thereafter until

the

principal repayment starts. Commencing on the principal repayment date March 1, 2022 and continuing on the first day of each month thereafter, the Company will make equal monthly payments of principal, together with applicable interest in arrears, to the Bank. The interest rate is set at 1% above the Prime Rate, which is defined in the Loan Agreement as the greater of 4.25% or the Prime Rate published in the Money Rates section of the Western Edition of the Wall Street Journal. The Prime Rate as of September 30, 2020 was 3.25%.

In connection with the Loan Agreement, the Company incurred approximately $141,000 of closing costs. The closing costs have been deduced from the carrying value of the debt and will be amortized through March 30, 2022, the maturity date of the Term Loan.

On April 27, 2021, the Company repaid its obligations in the aggregate amount of $7,354,283 and terminated the Loan Agreement with the Bank, and the Company’s collateral securing the facility was released. The Company accounted for this repayment and retirement as an extinguishment of the Loan Agreement. In addition to the outstanding principal and accrued interest, the Company was required to pay the $122,500 final payment, a termination fee of $50,000 and other closing costs totaling approximately $15,000. The Company also wrote off unamortized original closing costs as of the extinguishment date. The Company recorded a loss on extinguishment of approximately $386,000 related to the repayment and retirement of the Loan Agreement. The loss on extinguishment was composed of approximately $140,000 for a prepayment fee, $122,000 for the unaccrued final payment, $65,000 termination and other fees, and $58,000 for the unamortized and other closing costs from origination of the loan.

(b) Loan and Security Agreement – Silicon Valley Bank

On August 7, 2017, the Company entered into a Loan and Security Agreement, which was subsequently modified several times through November 1, 2019 (as amended, the “SVB Loan Agreement”), with Silicon Valley Bank that provided an initial term loan facility of $6.0 million and a $4.0 million revolving line of credit.

On March 30, 2020, the Company elected to repay all outstanding obligations (including accrued interest) and retire the SVB Loan Agreement. The Company accounted for this repayment and retirement as an extinguishment of the SVB Loan Agreement. In addition to the outstanding principal and accrued interest, the Company was required to pay the $510,000 final payment, a termination fee of $114,000 and other costs totaling $10,000. The Company also wrote off unamortized original closing costs as of the extinguishment date. In March 2020 the Company recorded a loss on extinguishment of approximately $341,000 related to the repayment and retirement of the SVB Loan Agreement. The loss on extinguishment was composed of approximately $185,000 for the unaccrued final payment, $114,000 termination fee, and $42,000 of unamortized and other closing costs.

Table of Contents

On December 20, 2018, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain institutional and accredited investors (the “Investors”), including, but not limited to, all directors and executive officers of the Company at the time, pursuant to which the Investors purchased unsecured subordinated convertible debentures (the “Convertible Debentures”) with an aggregate principal amount of approximately $7.0 million in a private placement.

On February 21, 2020 (the “Conversion Date”), the conditions permitting a forced conversion were met, and the Company elected to exercise its forced conversion right under the terms of the Convertible Debentures.

As a result of this election, all of the outstanding Convertible Debentures were converted, at a conversion price of $4.00 per share, into 1,742,500 shares of the Company’s common stock. In accordance with the make-whole provisions in the Convertible Debentures, the Company also issued an additional 76,966 shares of its common stock. The make-whole amount represented the total interest which would have accrued through the maturity date of the Convertible Debentures, less the amounts previously paid, totaling $697,000. The conversion prices related to the make-whole amount were dependent on whether the Investors were related parties or unrelated third parties.

Accounting Considerations and Fair Value Measurements Related to the Convertible Debentures

The Company had previously elected to make

a one-time, irrevocable

election to utilize the fair value option to account for the Convertible Debentures as a single hybrid instrument at its fair value, with changes in fair value from period to period being recorded either in current earnings, or as an element of other comprehensive income (loss), for the portion of the change in fair value determined to relate to the Company’s own credit risk. The Company believed that the election of the fair value option allowed for a more meaningful representation of the total fair value of its obligation under the Convertible Debentures and allowed for a better understanding of how changes in the external market environment and valuation assumptions impact such fair value.

As of the December 31, 2019 valuation and the prior measurement dates, the Company utilized a Monte Carlo simulation model to estimate the fair value of the Convertible Debentures. The simulation model was designed to capture the potential settlement features of the Convertible Debentures, in conjunction with simulated changes in the Company’s stock price and the probability of certain events occurring. The simulation utilized 100,000 trials or simulations to determine the estimated fair value.

The simulation utilized the assumptions that if the Company was able to exercise its forced conversion right (if the requirements to do so were met), that it would do so in 100% of such scenarios. Additionally, if an event of default occurred during the simulated trial (based on the Company’s probability of default), the Investors would opt to redeem the Convertible Debentures in 100% of such scenarios. If neither event occurred during a simulated trial, the simulation assumed that the Investor would hold the Convertible Debentures until the maturity date. The value of the cash flows associated with each potential settlement were discounted to present value in each trial based on either the risk-free rate (for an equity settlement) or the effective discount rate (for a redemption or cash settlement).

The Company also recorded a final adjustment to the Convertible Debentures based on their fair value on the Conversion Date, just prior to the forced conversion being completed. Given that the Company’s prior simulation model included the assumption that the Company would elect to force conversion in 100% of scenarios when the requirements were met, the final valuation was based on the actual results of the forced conversion. As such, the Company based the final fair value adjustment to the Convertible Debentures just prior to conversion on the number of shares of common stock that were issued to the Investors upon conversion and the fair value of the Company’s common stock as of the Conversion Date.

Table of Contents

The key inputs to the valuation models that were utilized to estimate the fair value of the Convertible Debentures included:


Input	December 31, 2019			February 21, 2020

Company’s stock price	$	7.77		$	11.64
Conversion price		4.00			4.00
Remaining term (years)		1.97			0.00
Equity volatility		49.00	%		N/A
Risk free rate		1.57	%		N/A
Probability of default event 1		0.45	%		N/A
Utilization of Forced Conversion (if available) 1		100.00	%		100.00	%
Exercise of Default Redemption (if available) 1		100.00	%		N/A
Effective discount rate 1		18.52	%		N/A

Represents a Level 3 unobservable input, as defined in Note 8—Fair Value Measurements, below.

The Company’s stock price was based on the closing stock price on the valuation date. The conversion price was based on the contractual conversion price included in the SPA.

The remaining term was determined based on the remaining time period to maturity of the Convertible Debentures, or remaining term under the expectation of the Company’s election of its forced conversion right.

The Company’s equity volatility estimate was based on the Company’s historical equity volatility, the Company’s implied and observed volatility of option pricing, and the historical equity and observed volatility of option pricing for a selection of public companies.

The risk-free rate was determined based on U.S. Treasury securities with similar terms.

The probability of the occurrence of a default event was based on Bloomberg’s

1-year

estimate of default risk for the Company (extrapolated over the remaining term).

The utilization of the forced conversion right and the default redemption right was based on management’s best estimate of both features being exercised upon the occurrence of the related contingent events.

The effective discount rate utilized at the December 31, 2019 valuation date was based on yields on

CCC-rated

debt instruments with terms equivalent to the remaining term of the Convertible Debentures. The credit rating estimate was based on the implied credit rating determined at issuance and no changes were identified by the Company that would impact this assessment.

Table of Contents

The fair value and principal value of the Convertible Debentures as of December 31, 2019 and the Conversion Date was as follows (in thousands):


Convertible Debentures	December 31, 2019		February 21, 2020

Fair value, in accordance with fair value option	$	13,642	$	21,164

Principal value outstanding	$	6,970	$	6,970

In February 2020 the Company recorded a loss from the change in fair value of the Convertible Debentures of approximately $7.5 million for period through the Conversion Date which is described in the additional fair value disclosures related to the Convertible Debentures in Note 8.

Upon the consummation of the forced conversion, the Company issued 1,816,466 shares of common stock with a fair value of approximately $21.2 million, which was reclassified to stockholders’ equity.

(d) Principal and Interest Payments Related to Financing Arrangements

The Company no longer has any financing agreements as of September 30, 2021.

The following amounts are included in interest expense in the Company’s consolidated statement of operations for the three and nine months ended September 30, 2021 and 2020 (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020

Cash interest expense	$	—	$	94	$	141	$	232
Interest on convertible debentures		—		—		—		49
Accrual of notes payable final payment		—		8		—		47
Amortization of debt costs		—		13		—		32

Total interest expense	$	—	$	115	$	141	$	360

Table of Contents

Note 5 – Lease Commitments

Under ASC 842, “Leases” (“ASC 842”), the Company determines if an arrangement contains a lease at inception. A lease is a contract, or part of a contract, that conveys the right to control the use of identified property, plant or equipment (i.e., an identified asset) for a period of time in exchange for consideration. Leases are classified as either operating leases or financing leases. At lease inception, the Company recognizes a lease liability equal to the present value of the remaining lease payments, and a right of use asset equal to the lease liability, subject to certain adjustments, such as for lease incentives. The Company uses its incremental borrowing rate to determine the present value of the lease payments. The Company determines the incremental borrowing rates for its leases by applying its applicable, fully collateralized borrowing rate, with adjustment as appropriate for the lease term. The lease term at the lease commencement date is determined based on the

non-cancellable

period for which the Company has the right to use the underlying asset, together with any periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option. The Company considers a number of factors when evaluating whether the options in its lease contracts are reasonably certain of exercise, such as length of time before option exercise, expected value of the leased asset at the end of the initial lease term, importance of the lease to overall operations, costs to negotiate a new lease, and any contractual or economic penalties.

Right-of-use

assets and obligations for short-term leases (leases with an initial term of 12 months or less) are not recognized in the consolidated balance sheet. Lease expense for short-term leases is recognized on a straight-line basis over the lease term. The Company does not sublease any of its leased assets to third parties. The Company’s lease agreements do not contain any residual value guarantees or restrictive covenants. The Company has lessor agreements that contain lease and

non-lease

components. As the Company has determined that the

non-lease

component of these agreements is the predominant component, the Company accounted for the complete agreement under ASC 606 upon adoption of ASC 842.

ASC 842 includes a number of reassessment and

re-measurement

requirements for lessees based on certain triggering events or conditions, including whether a contract is or contains a lease, assessment of lease term and purchase options, measurement of lease payments, assessment of lease classification and assessment of the discount rate. The Company reviewed the reassessment and

re-measurement

requirements and identified two lease modifications which are reflected in the table below showing the maturity of the Company’s lease liabilities as of September 30, 2021. This includes an extension of an operating lease for the facility leased by the Company in San Jose, California as well as some equipment. In addition, there were no impairment indicators identified during the quarter ended September 30, 2021 that required an impairment test for the Company’s

right-of-use

assets or other long-lived assets in accordance with ASC 360 10 “Property Plant and Equipment” (“ASC 360”).

Certain of the Company’s leases include variable lease costs to reimburse the lessor for real estate tax and insurance expenses, and certain

non-lease

components that transfer a distinct service to the Company, such as common area maintenance services. The Company has elected to not separate its accounting of lease components and

non-lease

components for real estate and equipment leases.

Table of Contents

Components of Leases:

The Company has leases for office space and office equipment. The leases have remaining lease terms ranging from less than one year to four years and six months as of September 30, 2021.

The components of lease expense for the three and nine months ended September 30, 2021 are as follows (in thousands):


Lease Cost	Classification	Three Months Ended September 30, 2021		Nine Months Ended September 30, 2021
Operating lease cost—Right of Use Asset	Operating expenses	$	214	$	649
Operating lease cost—Variable	Operating expenses		63	$	127

Total		$	277	$	776

Other information related to leases was as follows (in thousands):


	Three Months Ended September 30, 2021		Nine Months Ended September 30, 2021
Cash paid from operating cash flows for operating leases	$	230	$	581


	As of September 30, 2021

Weighted-average remaining lease term of operating leases (in years)		1.47
Weighted-average discount rate for operating leases		5.5	%

Table of Contents

Maturity of the Company’s lease liabilities as of September 30, 2021 was as follows (in thousands):


As of September 30, 2021:	Operating Leases

2021		229
2022		899
2023		211
2024		5

Total lease payments		1,344
Less: imputed interest		(57	)

Total lease liabilities		1,287
Less: current portion of lease liabilities		(856	)

Long-term lease liabilities	$	431

Note 6 – Stockholders Equity

(a) Financing Activity

On March 2, 2021, the Company entered into an underwriting agreement with Guggenheim Securities, LLC, as representative of the several underwriters thereto, in connection with an underwritten public offering of 1,393,738 shares of the Company’s common stock at an offering price of $18.00 per share. The offering closed on March 5, 2021 for gross proceeds of approximately $25.1 million and net proceeds of approximately $23.2 million to the Company.

Table of Contents

(b) Stock-Based Compensation

The Company

granted options to purchase 403,000 and 831,938 shares of the Company’s stock during the three and nine months e

nded

September 30, 2021 respectively. Options granted under the Company’s stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,

	2021		2020		2021		2020

Average risk-free interest rate	0.41	%	0.15	%	0.28	%	0.79	%
Expected dividend yield	None		None		None		None
Expected life	3.5 years		3.5 years		3.5 years		3.5 years
Expected volatility	65.57% to 67.42	%	66.0% to 66.0	%	65.57% to 67.42	%	50.2 to 65.7	%
Weighted average exercise price	$15.04		$8.84		$16.61		$10.08
Weighted average fair value	$6.18		$4.11		$7.34		$4.34


	Three Months Ended September 30,				Nine Months Ended September 30,

	2021		2020		2021		2020

Cost of revenue	$	3	$	3	$	20	$	28
Engineering and product development		73		64		281		406
Marketing and sales		149		61		629		608
General and administrative		431		337		1,172		1,500

	$	656	$	465	$	2,102	$	2,542

Table of Contents

As of September 30, 2021, unrecognized compensation cost (in thousands) related to unvested options and unvested restricted stock and the weighted average term of such equity instruments is as follows:


Remaining expense	$	4,972
Weighted average term		1.3

The Company’s restricted stock awards typically vest in either one year or three equal annual installments with the first installment vesting one year from the grant date.

The Company

did not grant any shares of restricted stock during the three-months ended September 30, 2021 or 2020. The Company granted 22,488 and 0 shares of restricted stock during the nine-months ended September 30, 2021 and 2020, respectively.

The Company’s aggregate intrinsic value for stock options and restricted stock outstanding is as follows (in thousands):


	As of September 30,

Aggregate intrinsic value	2021		2020
Stock options	$	8,765	$	6,679
Restricted stock		19		257

The Company

issued 54,702 and 138,450 shares of common stock upon the exercise of outstanding stock options in the three and nine-months ended September 30, 2021 respectively. The Company received cash proceeds of approximately $0.3

million and

$0.9

million

in the three and nine-months ended September 30, 2021 respectively. The intrinsic value of restricted shares that vested in the three and nine months ended September 30, 2021 was $0.0 million and $0.5 million respectively. There were 19,863 and 49,904 restricted shares that vested in the three and nine months ended September 30, 2021 respectively.

Employee Stock Purchase Plan

In December 2019, the 2019 Employee Stock Purchase Plan (“ESPP”) was adopted by the Company’s Board of Directors (the “Board”) and approved by stockholders, effective January 1, 2020.

The ESPP

provides for the issuance of up to 950,000 shares of common stock, subject to adjustment in the event of a stock split, stock dividend or other change in the Company’s capitalization. The ESPP may be terminated or amended by the Board at any time. Certain amendments to the ESPP require stockholder approval.

Substantially

all of the Company’s employees whose customary employment is for more than 20 hours a week are eligible to participate in the ESPP. Any employee who owns 5% or more of the voting power or value of the Company’s shares of common stock is not eligible to participate in the ESPP.

Table of Contents

Any eligible employee can enroll in the ESPP as of the beginning of a respective quarterly accumulation period. Employees who participate in the ESPP may purchase shares by authorizing payroll deductions of up to 15% of their base compensation during an accumulation period. Unless the participating employee withdraws from participation, accumulated payroll deductions are used to purchase shares of common stock on the last business day of the accumulation period (the “Purchase Date”) at a price equal to 85% of the lower of the fair market value on (i) the Purchase Date or (ii) the first day of such accumulation period. Under applicable tax rules, no employee may purchase more than $

25,000

worth of common stock, valued at the start of the purchase period, under the ESPP in any calendar year.

The Company issued 5,168 and 17,412 shares under the ESPP in the three and nine-months ended September 30, 2021 respectively. The Company recorded approximately $23,000 and $76,000 of stock-based compensation expense pursuant to ESPP for the three and nine-months ended September 30, 2021 respectively. The

accumulation period under the ESPP commenced on July 1, 2021 and ended on September 30, 2021, and the related shares purchased by the participants were issued in October 2021. As of September 30, 2021, the Company recorded a liability of approximately $89,000 related to employee withholdings in connection with the ESPP accumulation period ended September 30, 2021, which was included as a component of accrued expenses and other current liabilities.

Note 7 – Commitments and Contingencies

Other Commitments

The Company is obligated to pay approximately $4.3 million for firm purchase obligations to suppliers for future product and service deliverables and $0.2 million for minimum royalty obligations.

Litigation

In December 2016, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Invivo Corporation (“Invivo”). In accordance with the Asset Purchase Agreement, the Company sold to Invivo all right, title and interest to certain intellectual property relating to the Company’s VersaVue Software and DynaCAD product and related assets for $3.2 million. The Company closed the transaction on January 30, 2017 less a holdback reserve of $350,000 (the “Escrowed Amount”) for net proceeds of approximately $2.9 million.

On September 5, 2018, third-party Yeda Research and Development Company Ltd. (“Yeda”), filed a complaint (the “Complaint”) against the Company and Invivo in the United States District Court for the Southern District of New York, captioned Yeda Research and Development Company Ltd. v. iCAD, Inc. and Invivo Corporation, Case No.

1:18-cv-08083-GBD,

related to the Company’s sale of the VersaVue software and DynaCAD product under the Asset Purchase Agreement. Yeda alleged, among other things, that the Company infringed upon Yeda’s source code, which was originally licensed to the Company, by using it in the products that the Company sold to Invivo and that it is entitled to damages that could include, among other things, profits relating to the sales of these products. On April 13, 2021, the Company and Yeda entered into a Settlement and Release Agreement (the “Settlement Agreement”) whereby the Company furnished to Yeda a

one-time

cash payment of $85,000 and received a full,

non-conditional

release from Yeda of any and all claims related to the Complaint and the subject of the Complaint. Neither the Company nor Invivo acknowledged any wrongdoing at any point in connection with the Complaint or the subject matter thereof. The Escrowed Amount was reserved, in part, to cover any legal expenses related to the Asset Purchase Agreement and the transactions contemplated therein. The remaining balance of the Escrowed Amount following such expenses is due and payable to the Company in accordance with the terms of the Asset Purchase Agreement. The Company and Invivo agreed that Invivo would pay $50,000 of the Escrowed Amount and the Company expensed approximately $93,000 in the second quarter of 2021.

The Company may be a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it the ultimate resolution of which would have a material adverse effect on its financial condition or results of operations. However, should the Company fail to prevail in any legal matter or should several legal matters be resolved against the Company in the same reporting period, such matters could have a material adverse effect on the Company’s operating results and cash flows for that particular period. The Company may be a party to certain actions that have been filed against the Company which are being vigorously defended. The Company has determined that potential losses in these matters are neither probable or reasonably possible at this time. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, “Contingencies.” Legal costs are expensed as incurred.

Table of Contents

Note 8 – Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset

or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:

•

Level 1 - Quoted prices in active markets for identical assets or liabilities.

•

Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value.

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, and notes payable and convertible debentures. Due to their short-term nature and market rates of interest, the carrying amounts of the financial instruments (except the Convertible Debentures, which were measured at fair value in accordance with the fair value option election) approximated fair value as of February 21, 2020 and December 31, 2019.

The Company’s assets and liabilities that are measured at fair value on a recurring basis include the Company’s money market accounts and Convertible Debentures.

The money market accounts are included in cash and cash equivalents in the accompanying consolidated balance sheet and are considered a Level 1 measurement as they are valued at quoted market prices in active markets.

The Convertible Debentures were recorded as a separate component of the Company’s consolidated balance sheet and are considered a Level 3 measurement due to the utilization of significant unobservable inputs in their valuation. See Note 4(b) for a discussion of these fair value measurements.

The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands).


Fair Value Measurements as of December 31, 2020
	Level 1		Level 2		Level 3		Total

Assets
Money market accounts	$	27,186		—		—	$	27,186

Total Assets	$	27,186		—		—	$	27,186


Fair Value Measurements (in thousands) as of September 30, 2021
	Level 1		Level 2		Level 3		Total

Assets
Money market accounts	$	35,805		—		—	$	35,805

Total Assets	$	35,805		—		—	$	35,805

Table of Contents

Note 9 – Income Taxes

The Coronavirus Aid, Relief, and Economic Security Act was enacted on March 27, 2020 and did not have a material impact on the Company’s provision for income taxes for the three and nine months ended September 30, 2021.

The Company recorded an income tax provision of $0 for the three and nine months ended September 30, 2021, and $3,000 and $34,000 for the three and nine months ended September 30, 2020. The Company adopted ASU

2019-12

as of January 1, 2021, in accordance with this provision

non-income

and state franchise taxes are now classified as a component of operating expenses in General and Administrative expense. Income based tax expense will continue to be recognized as tax expense in the Consolidated Financial Statements. Tax expense for three and nine months ended September 30, 2020 represent

non-income

and state franchise tax, however the expense was not reclassified to operating expenses in accordance with ASU

2019-12.

The Company had no material unrecognized tax benefits and a deferred tax liability of approximately $4,000 related to tax amortizable goodwill. No other adjustments were required under ASC 740, “Income Taxes.” The Company does not expect that its unrecognized tax benefits will materially increase within the next 12 months. The Company did not recognize any interest or penalties related to uncertain tax positions at September 30, 2021.

The Company files United States federal income tax returns and income tax returns in various states and local jurisdictions. The Company’s three preceding tax years remain subject to examination by federal and state tax authorities. In addition, because the Company has net operating loss carry-forwards, the Internal Revenue Service and state jurisdictions are permitted to audit earlier years and propose adjustments up to the amount of net operating loss generated in those years. The Company is not currently under examination by any federal or state jurisdiction for any tax years.

Note 10 – Goodwill

The Company tests goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of the reporting unit is less than its carrying value.

The Company has two operating segments, Detection and Therapy, as further discussed in Note 12 below.

A rollforward of goodwill activity by reportable segment is as follows (in thousands)

	Consolidated reporting unit			Detection			Therapy			Total
Accumulated Goodwill	$	47,937		$	—		$	—		$	47,937
Accumulated impairment		(26,828	)		—			—			(26,828	)
Fair value allocation		(21,109	)		7,663			13,446			—
Acquisition of DermEbx and Radion		—			—			6,154			6,154
Acquisition measurement period adjustments		—			—			116			116
Acquisition of VuComp		—			1,093			—			1,093
Sale of MRI assets		—			(394	)					(394	)
Impairment		—			—			(19,716	)		(19,716	)

Balance at December 31, 2020 and September 30, 2021		—			8,362			—			8,362

There were no impairment indicators present as of September 30, 2021.

Note 11 – Long-lived assets

The Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than its carrying value.

There is no set interval or frequency for recoverability evaluation. Rather, the determination of when, if at all, an asset (or asset group) is evaluated for recoverability is based on “events and circumstances.”

The Company determined there were no such triggering events in the quarter ended September 30, 2021.

Table of Contents

Note 12 – Segment Reporting

Operating segments are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and assess performance.

The Company’s CODM is the Chief Executive Officer. Each reportable segment generates revenue from the sale of medical equipment and related services and/or sale of supplies. The Company has determined there are two segments, Detection and Therapy.

The Detection segment consists of the Company’s advanced image analysis and workflow products, and the Therapy segment consists of the Company’s radiation therapy products, “Axxent,” and related services. The primary factors used by the Company’s CODM to allocate resources are based on revenues, gross profit, operating income, and earnings or loss before interest, taxes, depreciation, amortization, and other specific and

non-recurring

items of each segment. Included in segment operating income are stock compensation, amortization of technology and depreciation expense. There are no intersegment revenues.

The Company does not track assets by operating segment and the Company’s CODM does not use asset information by segment to allocate resources or make operating decisions. Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to US GAAP loss before income tax is as follows (in thousands):


	Three Months Ended September 30,						Nine Months Ended September 30,
	2021			2020			2021			2020

Segment revenues:
Detection	$	6,008		$	5,291		$	16,515		$	13,885
Therapy		3,353			1,838			9,315			5,362

Total Revenue	$	9,361		$	7,129		$	25,830		$	19,247

Segment gross profit:
Detection	$	5,058		$	4,227		$	13,788		$	11,227
Therapy		1,654			798			4,751			2,665

Segment gross profit	$	6,712		$	5,025		$	18,539		$	13,892

Segment operating income (loss):
Detection	$	671		$	866		$	1,664		$	721
Therapy		(173	)		(711	)		(735	)		(2,149	)

Segment operating income (loss)	$	498		$	155		$	929		$	(1,428	)

General, administrative, depreciation and amortization expense	$	(2,679	)	$	(1,844	)	$	(7,513	)	$	(6,465	)
Interest expense		—			(115	)		(141	)		(360	)
Other income		5			10			12			85
Loss on extinguishment of debt		—			—			(386	)		(341	)
Fair value of convertible debentures		—			—			—			(7,464	)

Loss before income tax	$	(2,176	)	$	(1,794	)	$	(7,099	)	$	(15,973	)

Table of Contents

Note 13 – Recent Accounting Pronouncements

Recently Adopted Accounting Standards

In December 2019, the Financial Accounting Standard Board (the “FASB”) issued ASU

2019-12,

“Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” (“ASU

2019-12”).

ASU

2019-12

is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify US GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU

2019-12

is effective for the Company for the fiscal year and interim periods therein beginning January 1, 2021. The Company notes that the adoption of ASU

2019-12

resulted in the reclassification of an immaterial amount from income tax expense to

non-income

tax included in operating expenses related to the accounting for state and franchise taxes, with no impact to the Company’s consolidated income, equity or cash flows.

Recently Issued Accounting Standards Not Yet Adopted

In June 2016, the FASB issued

ASU 2016-13, “Financial

Instruments—Credit Losses (Topic 326)”

(“ASU 2016-13”),

which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost.

ASU 2016-13

replaces the existing incurred loss impairment model with an expected loss model which requires the use of forward-looking information to calculate credit loss estimates. These changes will result in earlier recognition of credit losses. In November 2019, the FASB elected to defer the adoption date of ASU

2016-13

for public business entities that meet the definition of a smaller reporting company to fiscal years beginning after December 15, 2022. Early adoption of the guidance in ASU

2016-13

is permitted. The Company is currently evaluating the impact that the adoption of ASU

2016-13

will have on its consolidated financial statements.

In March 2020, the FASB issued ASU

2020-04,

“Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU

2020-04”). ASU

2020-04

was issued because the London Interbank Offered Rate (“LIBOR”) is a benchmark interest rate referenced in a variety of agreements that are used by all types of entities, and at the end of 2021, banks will no longer be required to report information that is used to determine LIBOR. As a result, LIBOR is expected to be discontinued as a benchmark interest rate. Other interest rates used globally could also be discontinued for similar reasons. ASU

2020-04

provides companies with optional guidance to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. Companies can apply the ASU immediately. However, the guidance will only be available for a limited time (generally through December 31, 2022). The Company is currently evaluating the impact that the adoption of ASU

2020-04

will have on its consolidated financial statements.

In August 2020, the FASB issued ASU

2020-06,

“Debt – Debt with Conversion and Other Options (Subtopic

470-20)

and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic

815-40):

Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU

2020-06”).

ASU

2020-06

was issued to simplify the accounting for convertible instruments by removing major separation models required under current U.S. GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument and more convertible preferred stock as a single equity instrument with no separate accounting for embedded conversion features. ASU

2020-06

removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. ASU

2020-06

also simplifies the diluted earnings per share calculation in certain areas. ASU

2020-06

is effective for the Company for the fiscal year and interim periods therein beginning January 1, 2022. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU

2020-06

will have on its consolidated financial statements.

Note 14 – Subsequent Events

None.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Certain information included in this Item 2 and elsewhere in this Form

10-Q

that are not historical facts contain statements that may be deemed “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve or may involve a number of known and unknown risks, uncertainties and other factors that could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievement expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to following: the impact of the

COVID-19

pandemic on the Company’s business and the global economy; uncertainty of future sales and expense levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, regulatory changes and requirements applicable to the Company’s products, product market acceptance, possible technological obsolescence of products, increased competition, integration of acquired businesses, the impact of litigation and/or

Table of Contents

government regulation, changes in Medicare reimbursement policies, competitive factors, the effects of a decline in the economy in markets served by the Company and other risks detailed in the Company’s other filings with the Securities and Exchange Commission. The words “believe”, “plan”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, “seek”, “should”, “would”, “could” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date the statement was made. Except as required by law, iCAD undertakes no obligation to update any such forward-looking statements to reflect events or circumstances after the date of such statements.

Results of Operations

Overview

iCAD, Inc. is a global medical technology company providing innovative cancer detection and therapy solutions. The Company reports in two segments: Detection and Therapy.

In the Detection segment, the Company’s solutions include (i) advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, and (ii) a comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT).

In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer radiation treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.

On January 30, 2017, the Company completed the sale of certain intellectual property relating to the VersaVue Software and the DynaCAD product and related assets to Invivo for $3,200,000 in cash with a holdback amount of $350,000. The Company recently settled litigation with a third-party relating to this transaction, as further described in Note 7 hereto. The nine months ended September 30, 2020 and 2021 includes a $0.3 and $0.4 million charge related to the loss on the extinguishment of debt respectively, while the nine months ended September 30, 2020 included a $7.8 million charge related to the losses on the extinguishment of debentures and debt. In April 2021, the Company used approximately $7.4 million of cash to repay its credit facility in full.

The Company’s headquarters are located in Nashua, New Hampshire, with a manufacturing facility in New Hampshire and an operations, research, development, manufacturing and warehousing facility in San Jose, California.

COVID-19

Impact

On March 12, 2020, the World Health Organization declared

COVID-19

to be a pandemic. In an effort to contain and mitigate the spread of the

COVID-19

pandemic, the United States, many countries in Europe, as well as Canada and China, have imposed unprecedented restrictions on travel, and there have been business closures and a substantial reduction in economic activity in countries that have had significant outbreaks of

COVID-19.

As a provider of devices and services to the health care industry, the Company’s operations have been materially affected. Significant uncertainty remains as to the continuing impact of the

COVID-19

pandemic on the Company’s operations and on the global economy as a whole. It is currently not possible to predict how long the pandemic will last or the time that it will take for economic activity to return to prior levels. The

COVID-19

pandemic has resulted in significant financial market volatility and uncertainty. A worsening level of market disruption and volatility seen in the recent past will have an adverse effect on the Company’s ability to access capital, on the Company’s business, results of operations and financial condition, and on the market price of the Company’s common stock. The Company’s results for the quarter ending September 30, 2021, as well as our results for all prior quarters beginning with Q1 2020, reflect a negative impact from the

COVID-19

pandemic, due to some healthcare facilities’ additional focus on

COVID-19

and from the effect on our customers and potential customers of supply chain issues relating thereto. Although the Company does not provide guidance to investors relating to the Company’s results of operations, the Company’s results for the quarter ending December 31, 2021, and possibly future quarters, could reflect a continued negative impact from the

COVID-19

pandemic for similar reasons.

During the first quarter of fiscal 2020, the Company entered into an equity distribution agreement with JMP Securities to provide for an

at-

the-market

offering program to provide additional potential liquidity through the sale of common stock having a value of up to $25.0 million (the “ATM Facility”). On December 17, 2020 the Company sold 470,704 shares of common stock under the ATM Facility for gross proceeds of approximately $6.6 million and net proceeds of approximately $6.1 million. On March 2, 2021, the Company terminated the ATM Facility. Also on March 2, 2021, the Company entered into an underwriting agreement with Guggenheim Securities, LLC, as representative of the several underwriters thereto, in connection with an underwritten public offering of 1,393,738 shares of the Company’s common stock at an offering price of $18.00 per share. The offering closed on March 5, 2021 for gross proceeds of approximately $25.1 million and net proceeds of approximately $23.2 million to the Company. The Company believes that its current liquidity and capital resources are sufficient to sustain operations through at least the next 12 months, primarily due to cash on hand of $35.8 million at September 30, 2021 and anticipated revenue and cash collections. However, the resurgence of the

COVID-19

pandemic could affect the Company’s liquidity.

Table of Contents

Critical Accounting Estimates

The Company’s discussion and analysis of its financial condition, results of operations, and cash flows are based on the Company’s consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States.

The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates these estimates, including those related to revenue recognition, allowance for doubtful accounts, inventory valuation and obsolescence, intangible assets, goodwill, income taxes, contingencies, and litigation. Additionally, the Company uses assumptions and estimates in calculations to determine stock-based compensation, the fair value of convertible debentures, and evaluation of litigation. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Due to the

COVID-19

pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form

10-Q.

These estimates may change, as new events occur, and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.

Other than as described herein, there have been no additional material changes to the Company’s critical accounting policies as discussed in the Company’s Annual Report on Form

10-K

for the fiscal year ended December 31, 2020 filed with the SEC on March 15, 2021 (the “2020

10-K”).

For a comprehensive list of the Company’s critical accounting policies, reference should be made to the 2020

10-K.

Table of Contents

Three and nine months ended September 30, 2021 compared to three and nine months ended September 30, 2020.

Revenue: (in thousands)

Three months ended September 30, 2021 and 2020:


	Three months ended September 30,
	2021		2020		Change		% Change
Detection revenue
Product revenue	$	4,454	$	3,889	$	565		14.5	%
Service and supplies revenue		1,554		1,402		152		10.8	%

Subtotal		6,008		5,291		717		13.6	%

Therapy revenue
Product revenue		1,866		649		1,217		187.5	%
Service and supplies revenue		1,487		1,189		298		25.1	%

Subtotal		3,353		1,838		1,515		82.4	%

Total revenue	$	9,361	$	7,129	$	2,232		31.3	%

Total revenue increased by approximately $2.2 million, or 31.3%, from $7.1 million for the three months ended September 30, 2020 to $9.4 million for the three months ended September 30, 2021. The increase is due to an increase in Therapy revenue of approximately $1.5 million and Detection revenue of $0.7 million.

Detection product revenue increased by approximately $0.6 million, or 14.5%, from $3.9 million for the three months ended September 30, 2020 to $4.5 million for the three months ended September 30, 2021. The overall increase is due primarily to an increase in direct customer revenue of $0.4 million and an increase in original equipment manufacturer customer revenue of $0.2 million, in each case relating primarily to revenue from 3D imaging and density assessment products.

Detection service and supplies revenue, which is primarily sold to direct customers, increased by $0.2 million, or 10.8%, from $1.4 million in the three months ended September 30, 2020 to $1.6 million in the three months ended September 30, 2021.

Therapy product revenue increased by approximately $1.2 million, or 187.5%, from $0.7 million for the three months ended September 30, 2020 to $1.9 million for the three months ended September 30, 2021. Therapy product revenue is related to the sale of the Company’s Axxent systems and can vary significantly from quarter to quarter due to changes in the number of units sold, and the average selling price. The Company believes that Therapy product revenue was adversely affected by the

COVID-19

pandemic during the three months ended September 30, 2020, due to

stay-at-home

and social distancing orders as well as the uncertainty in the market.

Therapy service and supplies revenue increased by approximately $0.3 million, or 25.1%, from $1.2 million for the three months ended September 30, 2020 to $1.5 million for the three months ended September 30, 2021. The Company believes that Therapy service and supplies revenue, specifically the use of balloons for procedures, was adversely affected by the

COVID-19

pandemic during the three months ended September 30, 2020, due to

stay-at-home

and social distancing orders as well as the uncertainty in the market. The Company saw higher service and supplies revenues due to higher balloon sales in the three months ended September 30, 2021 as compared to the three months ended September 30, 2020. The Company is not able to predict how the

COVID-19

pandemic will affect future Therapy service and supplies revenue.

Table of Contents

Nine months ended September 30, 2021 and 2020:


	Nine months ended September 30,
	2021		2020		Change		% Change
Detection revenue
Product revenue	$	11,779	$	9,691	$	2,088		21.5	%
Service revenue	$	4,736		4,194		542		12.9	%

Subtotal		16,515		13,885		2,630		18.9	%

Therapy revenue
Product revenue	$	4,650		1,529		3,121		204.1	%
Service revenue	$	4,665		3,833		832		21.7	%

Subtotal		9,315		5,362		3,953		73.7	%

Total revenue	$	25,830	$	19,247	$	6,583		34.2	%

Total revenue increased by approximately $6.6 million, or 34.2%, from $19.2 million for the nine months ended September 30, 2020 to $25.8 million for the nine months ended September 30, 2021. The increase is due to an increase in Therapy revenue of approximately $4.0 million and an increase in Detection revenue of $2.6 million.

Detection

product revenue increased by approximately $2.1 million, or 21.5%, from $9.7 million for the nine months ended September 30, 2020 to $11.8 million for the nine months ended September 30, 2021. The overall increase is due primarily to an increase in direct customer revenue from 3D imaging and density assessment products. The Company believes that the

COVID-19

pandemic also adversely affected revenues during the nine months ended September

30, 2020.

Detection service and supplies revenue, which is primarily sold to direct customers, increased by $0.5 million, or 12.9%, from $4.2 million in the nine months ended September 30, 2020 to $4.7 million in the nine months ended September 30, 2021.

Therapy product revenue increased by approximately $3.1 million, or 204.1%, from $1.5 million for the nine months ended September 30, 2020 to $4.6 million for the nine months ended September 30, 2021. Therapy product revenue is related to the sale of the Company’s Axxent systems and can vary significantly from quarter to quarter due to changes in the number of units sold, and the average selling price. The Company believes that Therapy product revenue was adversely affected by the

COVID-19

pandemic during the nine months ended September 30, 2020, due to

stay-at-home

and social distancing orders as well as the uncertainty in the market.

Therapy service and supplies revenue increased by approximately $0.8 million, or 21.7%, from $3.8 million for the nine months ended September 30, 2020 to $4.7 million for the nine months ended September 30, 2021. The Company believes that Therapy service and supplies revenue, primarily the use of balloons for procedures, was adversely affected by the

COVID-19

pandemic during the nine months ended September 30, 2020, due to

stay-at-home

and social distancing orders as well as the uncertainty in the market. The Company saw higher service and supplies revenues due to higher balloon sales in the nine months ended September 30, 2021 as compared to the nine months ended September 30, 2020. The Company is not able to predict how the

COVID-19

pandemic will affect future Therapy service and supplies revenue.

Table of Contents

Cost of Revenue and Gross Profit: (in thousands)

Three months ended September 30, 2021 and 2020:


	Three months ended September 30,
	2021		2020		Change			% Change
Products	$	1,807	$	1,345	$	462			34.3	%
Service and supplies		763		667		96			14.4	%
Amortization and depreciation		79		92		(13	)		(14.1	)%

Total cost of revenue	$	2,649	$	2,104	$	545			25.9	%

Gross profit	$	6,712	$	5,025	$	1,687			33.6	%


	Three months ended September 30,
	2021		2020		Change		% Change
Detection gross profit	$	5,058	$	4,227	$	831		19.7	%
Therapy gross profit		1,654		798		856		107.3	%

Gross profit		6,712		5,025		1,687		33.6	%

Table of Contents

Gross profit for the three months ended September 30, 2021 was approximately $6.7 million, or 71.7% of revenue, as compared to $5.0 million, or 70.5% of revenue, for the three months ended September 30, 2020. The

COVID-19

pandemic adversely affected revenues from Detection products and the Therapy segment in the three months ended September 30, 2020, which resulted in lower gross profit in both segments in 2020. The higher gross profit as a percentage of sales in the three months ended September 30, 2021 was primarily related to product mix, with lower margin Therapy products being a greater percentage of total sales in the three months ended September 30, 2021 than in the three month period ended September 30, 2020.

Cost of products increased by approximately $0.5 million, or 34.3%, from $1.3 million for the three months ended September 30, 2020 to $1.8 million for the three months ended September 30, 2021. Cost of product revenue as a percentage of product revenue was approximately 29.6% for the three months ended September 30, 2020 as compared to 28.6% for the three months ended September 30, 2021. The increase in cost of products is primarily due to the increased sales in both Therapy and Detection. The decrease in cost of products as a percentage of product revenue in the three months ended September 30, 2021 was primarily due to a hardware upgrade sale for the Detection business with a lower than standard average selling price in the three months ended September 30, 2020.

Cost

of service and supplies increased by approximately $0.1 million, or 14.4%, from $0.7 million for the three months ended September 30, 2020 to $0.8 million for the three months ended September 30, 2021. Cost of service and supplies revenue as a percentage of service and supplies revenue was approximately 25.7% for the three months ended September 30, 2020 as compared to 25.1% for the three months ended September 30, 2021. The lower cost of service and supplies as a percentage of sales in the three months ended September 30, 2021 was primarily related to an overall increase in service and supplies revenue of approximately 17.4% in the three month period ended September 30, 2021 compared to the three month period ended September 30, 2020 with only a limited increase in personnel costs

Amortization and depreciation, which relates primarily to acquired intangible assets and depreciation of machinery and equipment, was approximately $0.1 million for the three months ended September 30, 2021 and 2020.

Nine months ended September 30, 2021 and 2020:


	2021		2020		Change			% Change
Products	$	4,592	$	2,899	$	1,693			58.4	%
Service and supplies		2,462		2,169		293			13.5	%
Amortization and depreciation		237		287		(50	)		(17.4	)%

Total cost of revenue	$	7,291	$	5,355	$	1,936			36.2	%

Gross profit	$	18,539	$	13,892	$	4,647			33.5	%


	Nine months ended September 30,
	2021		2020		Change		% Change
Detection gross profit	$	13,788	$	11,227	$	2,561		22.8	%
Therapy gross profit		4,751		2,665		2,086		78.3	%

Gross profit		18,539		13,892		4,647		33.5	%

Gross profit for the nine months ended September 30, 2021 was approximately $18.5 million, or 71.8% of revenue, as compared to $13.9 million, or 72.2% of revenue, for the nine months ended September 30, 2020. The

COVID-19

pandemic adversely affected revenues from Detection products and the Therapy segment in the nine month ended September 30, 2020, which

Table of Contents

resulted in lower gross profit in both segments in 2020. The higher gross profit as a percentage of sales in the nine months ended September 30, 2020 was primarily related to product mix, with lower margin Therapy products being a greater percentage of total sales in the nine months ended September 30, 2021 than in the nine month period ended September 30, 2020.

Cost of products increased by approximately $1.7 million, or 58.4%, from $2.9 million for the nine months ended September 30, 2020 to $4.6 million for the nine months ended September 30, 2021. Cost of product revenue as a percentage of product revenue was approximately 25.8% for the nine months ended September 30, 2020 as compared to 28.0% for the nine months ended September 30, 2021. The increase in cost of products is primarily due to the increased sales in both Therapy and Detection resulting in increases in cost of products of $1.6 and $0.1 million respectively. The higher cost of products as a percentage of sales in the nine months ended September 30, 2021 was primarily related to product mix, with lower margin Therapy products being a greater percentage of total sales in the nine months ended September 30, 2021 than in the nine month period ended September 30, 2020.

Cost

of service and supplies increased by approximately $0.3 million, or 13.5%, from $2.2 million for the nine months ended September 30, 2020 to $2.5 million for the nine months ended September 30, 2021. Cost of service and supplies revenue as a percentage of service and supplies revenue was approximately 27.0% for the nine months ended September 30, 2020 as compared to 26.2% for the nine months ended September 30, 2021. The lower cost of service and supplies as a percentage of sales in the nine months ended September 30, 2021 was primarily related to an overall increase in service and supplies revenue of approximately 17.1% in the nine month period ended September 30, 2021 compared to the nine month period ended September 30, 2020 with only limited increase in personnel

costs

Amortization and depreciation, which relates primarily to acquired intangible assets and depreciation of machinery and equipment, was approximately $0.3 million for the nine months ended September 30, 2020 as compared to $0.2 million for the nine months ended September 30, 2021.

Operating Expenses: (in thousands)

Three months ended September 30, 2021 and 2020:


	Three months ended September 30,
	2021		2020		Change		Change %
Operating expenses:
Engineering and product development	$	2,285	$	1,849	$	436		23.6	%
Marketing and sales		3,886		2,979		907		30.4	%
General and administrative		2,658		1,834		824		44.9	%
Amortization and depreciation		64		52		12		23.1	%

Total operating expenses	$	8,893	$	6,714	$	2,179		32.5	%

Operating expenses increased by approximately $2.2 million, or 32.5%, from $6.7 million in the three months ended September 30, 2020 to $8.9 million in the three months ended September 30, 2021. The Company took steps throughout 2020 to reduce operating expenses during the

COVID-19

pandemic and this was evident in the three-months ended September 30, 2020. The Company has since reinstated furloughed employees and resumed some business travel based on relaxation of

COVID-19

restrictions and the strength of the business, but the Company continues to take a disciplined approach with expenses, given the lingering risk of

COVID-19

related negative impacts to the business.

Engineering and Product Development

. Engineering and product development costs increased by approximately $0.4 million, or 23.6%, from $1.9 million for the three months ended September 30, 2020 to $2.3 million for the three-months ended September 30, 2021. The increase is primarily due to personnel costs related to reinstatement of furloughed employees.

Marketing and Sales

. Marketing and sales expenses increased by approximately $0.9 million, or 30.4%, from $3.0 million in the three months ended September 30, 2020, to $3.9 million in the three months ended September 30, 2021. Detection marketing and sales increased by approximately $0.7 million and Therapy marketing and sales increased by $0.2 million. The increases are primarily due to personnel costs and increased travel as compared to the three months ended September 30, 2020 when travel was impacted by the

COVID-19

pandemic.

General and Administrative

. General and administrative expenses increased by approximately $0.8 million, or 44.9%, from $1.8 million in the three months ended September 30, 2020 to $2.7 million for the three months ended September 30, 2021. The increase is primarily due to personnel costs related to reinstatement of furloughed employees, new hires, consulting costs, and costs associated with recruiting personnel across the organization.

Table of Contents

Amortization and Depreciation.

Amortization and depreciation, which relates primarily to acquired intangible assets and depreciation of machinery and equipment, increased by approximately $12,000, or 23.1% from $52,000 for the three months ended September 30, 2020 to $64,000 for the three months ended September 30, 2021.

Other Income and Expense: (in thousands)

Three months ended September 30, 2021 and 2020:


	Three months ended September 30,
	2021		2020			Change			Change %
Interest expense	$	—	$	(115	)	$	115			(100.0	)%
Other income		5		10			(5	)		(50.0	)%

	$	5	$	(105	)	$	110			(104.8	)%

Tax benefit (expense)	$	—	$	(3	)	$	3			(100.0	)%

Interest expense

. Interest expense decreased $115,000, or 100%, from $115,000 in the three months ended September 30, 2020 to $0 for the three months ended September 30, 2021. The decrease is due to the timing of termination of the Loan Agreement.

Other income

. Other income decreased by approximately $5,000, or 50.0%, from $10,000 for the three months ended September 30, 2020 to $5,000 for the three months ended September 30, 2021.

Tax expense

. Tax expense decreased by approximately $3,000, or 100%, from $3,000 for the three months ended September 30, 2020 to $0 for the three months ended September 30, 2021. The Company has approximately $42,000 in

non-income

related tax expense classified in operating expenses under ASU

2019-12

that had previously been classified here in tax expense. Tax expense includes state

non-income

and franchise-based taxes.

Operating Expenses: (in thousands)

Nine months ended September 30, 2021 and 2020:


	Nine months ended September 30,
	2021		2020		Change		Change %
Operating expenses:
Engineering and product development	$	6,745	$	5,938	$	807		13.6	%
Marketing and sales		10,739		9,218		1,521		16.5	%
General and administrative		7,461		6,476		985		15.2	%
Amortization and depreciation		178		153		25		16.3	%

Total operating expenses	$	25,123	$	21,785	$	3,338		15.3	%

Operating expenses increased by approximately $3.3 million, or 15.3%, from $21.8 million in the nine months ended September 30, 2020 to $25.1 million in the nine months ended September 30, 2021. The Company took steps throughout 2020 to reduce operating expenses during the

COVID-19

pandemic and this was evident in the nine months ended September 30, 2020. The Company has since reinstated furloughed employees and resumed some business travel based on relaxation of

COVID-19

restrictions and the strength of the business, but the Company continues to take a disciplined approach with expenses, given the lingering risk of

COVID-19

related negative impacts to the business.

Engineering and Product Development

. Engineering and product development costs increased by approximately $0.8 million, or 13.6%, from $5.9 million for the nine months ended September 30, 2020, to $6.7 million for the nine months ended September 30, 2021. The increase is primarily due to personnel costs related to reinstatement of furloughed employees.

Marketing and Sales

. Marketing and sales expenses increased by approximately $1.5 million, or 16.5%, from $9.2 million in the nine months ended September 30, 2020, to $10.7 million in the nine months ended September 30, 2021. Detection marketing and sales increased by approximately $1.1 million and Therapy marketing and sales increased by $0.4 million. The increases are primarily due to personnel costs including new hires, commissions on higher sales, and increased travel as compared to the nine months ended September 30, 2020 when travel was impacted by the

COVID-19

pandemic.

Table of Contents

General and Administrative

. General and administrative expenses increased by approximately $1.0 million, or 15.2%, from $6.5 million in the nine months ended September 30, 2020 to $7.5 million for the nine months ended September 30, 2021. The increase is primarily due to personnel costs related to reinstatement of furloughed employees, new hires, consulting costs, and costs associated with recruiting personnel across the organization.

Amortization and Depreciation.

Amortization and depreciation which relates primarily to acquired intangible assets and depreciation of machinery and equipment, increased by approximately $25,000, or 16.3% from $153,000 for the nine months ended September 30, 2020, to $178,000 for the nine months ended September 30, 2021.

Other Income and Expense: (in thousands)

Nine months ended September 30, 2021 and 2020:


	Nine months ended September 30,
	2021			2020			Change			Change %
Interest expense	$	(141	)	$	(360	)	$	219			(60.8	)%
Other income		12			85			(73	)		(85.9	)%
Loss on extinguishment of debt		(386	)		(341	)		(45	)		13.2	%
Loss on fair value of debentures		—			(7,464	)		7,464			(100.0	)%

	$	(515)		$	(8,080	)	$	7,565			(93.6	)%

Tax benefit (expense)	$	—		$	(34	)	$	34			(100.0	)%

Interest expense

. Interest expense decreased $219,000, or 60.8%, from $360,000 in the nine months ended September 30, 2020 to $141,000 for the nine months ended September 30, 2021. The decrease is due to the timing of termination of the Loan Agreement.

Other income

. Other income decreased by approximately $73,000, or 85.9%, from $85,000 for the nine months ended September 30, 2020 to $12,000 for the nine months ended September 30, 2021.

Loss on extinguishment of debt:

The Company recorded a loss on extinguishment of approximately $386,000 related to the repayment and retirement of the Loan Agreement as of the nine months ended September 30, 2021. The loss on extinguishment was composed of approximately $140,000 for a prepayment fee, $122,000 for the unaccrued final payment, $65,000 termination, and other fees, and $58,000 for the unamortized and other closing costs from opening the loan. In March 2020 the Company recorded a loss on extinguishment of approximately $341,000 related to the repayment and retirement of the SVB Loan Agreement. The loss on extinguishment was composed of approximately $185,000 for the unaccrued final payment, $114,000 termination fee, and $42,000 of unamortized and other closing costs.

Loss on fair value of debentures

. The Company recorded a loss of approximately $7.5 million in the nine months ended September 30, 2020, which reflected an increase in the fair value of the unsecured subordinated convertible debentures issued in December 2018 from $13.7 million as of December 31, 2019 to $21.2 million as of February 21, 2020. Upon the consummation of the forced conversion of the debentures, the Company issued 1,816,466 shares of common stock with a fair value of approximately $21.2 million, which was reclassified to stockholders’ equity during the nine-months ending September 30, 2020. As a result of the forced conversion there was no fair value adjustment for the nine months ended September 30, 2021.

Tax expense

. Tax expense decreased by approximately $34,000, or 100%, from $34,000 for the nine months ended September 30, 2020 to $0 for the nine months ended September 30, 2021. The Company has approximately $98,000 in

non-income

related tax expense classified in operating expenses under ASU

2019-12

that had previously been classified here in tax expense. Tax expense includes state

non-income

and franchise-based taxes.

Table of Contents

Liquidity and Capital Resources

The Company believes that its cash and cash equivalents balance of $35.8 million as of September 30, 2021, and projected cash balances are sufficient to sustain operations for at least the next twelve months following the filing of this Form

10-Q.

The Company’s ability to generate cash adequate to meet its future capital requirements will depend primarily on operating cash flow. If sales or cash collections are reduced from current expectations, or if expenses and cash requirements are increased, the Company may require additional financing, although there are no guarantees that the Company will be able to obtain the financing if necessary. In addition, the resurgence of the

COVID-19

pandemic could affect the Company’s liquidity. The Company will continue to closely monitor its liquidity and the capital and credit markets.

The Company’s cash on hand as of September 30, 2021 includes proceeds from the March 2, 2021 underwritten public offering described below. On April 27, 2021, the Company repaid its obligations in the aggregate amount of $7,354,283 under and terminated the Loan Agreement entered into with the Bank on March 30, 2020 and amended on June 22, 2020 and the Company’s collateral securing the facility was released.

On April 27, 2020, the Company issued 1,562,500 shares of common stock to several institutional investors at a price of $8.00 per share in a registered direct offering. The gross proceeds of the offering were approximately $12.5 million, and the Company received net proceeds of approximately $12.3 million. The Company also entered into the ATM Facility with JMP Securities in March 2020 to provide for additional potential liquidity. The ATM facility provided for the sale of common stock having a value of up to $25.0 million. On December 17, 2020 the Company sold 470,704 shares of common stock under the ATM Facility for gross proceeds of approximately $6.6 million and net proceeds of approximately $6.1 million. As of December 31, 2020, $18.4 million in capacity remained under the ATM Facility. On March 2, 2021, the Company terminated the ATM Facility.

The Company had net working capital of $38.0 million as of September 30, 2021. The ratio of current assets to current liabilities as of September 30, 2021 and December 31, 2020 was 3.53 and 2.53 respectively.


	For the nine months ended September 30,
	2021			2020
	(in thousands)
Net cash used for operating activities	$	(7,861	)	$	(6,083	)
Net cash used for investing activities		(450	)		(286	)
Net cash provided by financing activities		16,930			13,689

Increase in cash and equivalents	$	8,619		$	7,320

Net cash used for operating activities for the nine months ended September 30, 2021 was $7.9 million, compared to $6.1 million for the nine months ended September 30, 2020. The net cash used for operating activities for the nine months ended September 30, 2021 primarily reflects the Company’s net loss and working capital changes resulting from decreases in accounts payable and accrued expenses as well as an increase in accounts receivable offset by a decrease in prepaid and other assets. iCAD expects that net cash used for or provided by operating activities may fluctuate in future periods as a result of a number of factors, including fluctuations in the Company’s operating results, the timing of when the Company recognizes revenue, collections of accounts receivable and the timing of other payments.

Net cash used for investing activities for the nine months ended September 30, 2021 was $450,000, compared to $286,000 for the nine months ended September 30, 2020. The net cash used for investing activities for the nine months ended September 30, 2021 and 2020 was primarily for purchases of property and equipment.

Net cash provided by financing activities for the nine months ended September 30, 2021 was $16.9 million, compared to $13.7 million for the nine months ended September 30, 2020. Net cash provided by financing activities for the nine months ended September 30, 2021 was primarily from the March 2, 2021 underwritten public offering of 1,393,738 shares of the Company’s common stock at an offering price of $18.00 per share resulting in net proceeds of approximately $23.2 million. This was offset by repayment of the Loan Agreement to the Bank. The company also received $0.9 million from the issuance of

Table of Contents

common stock pursuant the Company’s stock option plan and $0.2 million for from the issuance of common stock pursuant the Employee Stock Purchase Plan. Net cash provided by financing activities for the nine months ended September 30, 2020 was $13.7 million primarily from the $12.3 million in net proceeds from the issuance of common stock and $7.0 million from the Loan Agreement with the Bank, offset by $4.6 million in repayment of the term loan with SVB and $2.0 million in repayment of the revolving loan with SVB.

Recent Accounting Pronouncements

See Note 13 to the Condensed Consolidated Financial Statements.

Item

Quantitative and Qualitative Disclosures about Market Risk

The Company believes that it is not subject to material foreign currency exchange rate fluctuations, as substantially all of its sales and expenses are denominated in the U.S. dollar. The Company does not hold derivative securities and has not entered into contracts embedded with derivative instruments, such as foreign currency and interest rate swaps, options, forwards, futures, collars or warrants, either to hedge existing risks or for speculative purposes.

Item

Controls and Procedures

The Company’s management, with the participation of its principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of its disclosure controls and procedures as of the end of the period covered by this report. Based on this evaluation, as of September 30, 2021, the principal executive officer and principal financial officer concluded that the Company’s disclosure controls and procedures (as defined in Rule

13a-15(e)

of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) were effective at a reasonable level of assurance.

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. The Company conducts periodic evaluations to enhance, where necessary, its controls and procedures.

The Company’s principal executive officer and principal financial officer conducted an evaluation of the Company’s internal control over financial reporting (as defined in Rule

13a-15(f)

of the Exchange Act) and have determined there are no changes in its internal controls over financial reporting during the quarter ended September 30, 2021 that have materially affected or which are reasonably likely to materially affect internal control over financial reporting.

Table of Contents

PART II OTHER INFORMATION

Item

1A.

Risk Factors:

iCAD operates in a changing environment that involves numerous known and unknown risks and uncertainties that could materially adversely affect the Company’s operations. In addition to the risk factor below, factors that have affected the Company are described in Part I, Item 1A of the Company’s Annual Report on Form

10-K

for the year ended December 31, 2020 as filed with the SEC on March 15, 2021 and are incorporated by reference herein.

iCAD expects the novel coronavirus

(COVID-19)

pandemic to have a significant effect on the Company’s results of operations. In addition, it has resulted in significant financial market volatility, and its impact on the global economy appears to be significant. A worsening of the pandemic will have a material adverse impact on the Company’s business, results of operations and financial condition and on the market price of the Company’s common stock.

On March 12, 2020, the World Health Organization declared

COVID-19

to be a pandemic. In an effort to contain and mitigate the spread of the

COVID-19

COVID-19.

As a provider of devices and services to the health care industry, the Company’s operations have been materially affected. Significant uncertainty remains as to the impact of the

COVID-19

pandemic has resulted in significant financial market volatility and uncertainty. A worsening of the levels of market disruption and volatility seen in the recent past will have an adverse effect on the Company’s ability to access capital, on the Company’s business, results of operations and financial condition, and on the market price of the Company’s common stock. The Company’s results for the quarter ending September 30, 2021 reflect a negative impact from the

COVID-19

pandemic due to some healthcare facilities’ additional focus on

COVID-19

and from the effect on our customers and potential customers of supply chain issues relating thereto. Although the Company does not provide guidance to investors relating to our results of operations, the Company’s results for the quarter ending December 31, 2021, and possibly future quarters, could reflect a negative impact from the

COVID-19

pandemic for similar reasons. Depending upon the duration and severity of the pandemic, the effect on the Company’s results over the long term is uncertain.

The Company’s exposure to trade accounts receivable losses may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current

COVID-19

pandemic, or other customer-specific factors. The Company has historically not experienced significant trade account receivable losses, but it is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade account receivables as hospitals’ cash flows are impacted by their response to the

COVID-19

pandemic.

Table of Contents

Item 6.

Exhibits


Exhibit No.		Description

3.1		Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q filed on August 6, 2021).

10.1		2016 Stock Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed on August 6, 2021).

10.2		Employment Agreement dated August 4, 2021, by and between iCAD, Inc. and Charles Carter (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on August 6, 2021).

31.1*		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**		Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**		Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101*		The following materials formatted in XBRL (eXtensible Business Reporting Language); (i) Condensed Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020, (ii) Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2021 and 2020, (iii) Condensed Consolidated Statements of Cash Flows for the three and nine months ended September 30, 2021 and 2020, (iv) Condensed Statements of Stockholders’ Equity for the three and nine months ended September 30, 2021 and September 30, 2020 and (v) Notes to Condensed Consolidated Financial Statements.

104*		Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101).

*	Filed herewith

**	Furnished herewith

Table of Contents

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

iCAD, Inc.

(Registrant)

Large Accelerated filer

Accelerated filer

Non-accelerated
filer

Smaller reporting company

Emerging growth company